FDG-PET Imaging in Cardiac Sarcoidosis : Importance of the pathological findings in the right ventricle by Tuominen, Heikki
Tampere University Dissertations 206
FDG-PET Imaging in 
Cardiac Sarcoidosis
,PSRUWDQFHRIWKHSDWKRORJLFDO¿QGLQJV
in the right ventricle
HEIKKI TUOMINEN

Tampere University Dissertations 206  
HEIKKI TUOMINEN 
FDG-PET Imaging in 
Cardiac Sarcoidosis 
Importance of the pathological findings  
in the right ventricle 
ACADEMIC DISSERTATION 
To be presented, with the permission of 
the Faculty of Medicine and Health Technology 
of Tampere University, 
for public discussion in the A210-201 
of the Arvo building, Arvo Ylpön katu 34, Tampere, 
on 14 February, at 12 o’clock. 
  
ACADEMIC DISSERTATION 
Tampere University, Faculty of Medicine and Health Technology 
Finland 
 
 
Responsible 
supervisor 
and Custos 
Professor Mika Kähönen 
Tampere University 
Finland 
 
Supervisor Professor Mika Kähönen 
Tampere University 
Finland 
 
Pre-examiners Docent Tuula Janatuinen 
University of Turku 
Finland 
Docent Jukka Lehtonen 
University of Helsinki 
Finland 
Opponent Docent Jukka Kemppainen 
University of Turku 
Finland 
 
 
 
   
 
 
The originality of this thesis has been checked using the Turnitin OriginalityCheck 
service. 
 
 
Copyright ©2020 author 
 
 
Cover design: Roihu Inc. 
 
 
 
 
 
ISBN 978-952-03-1426-2 (print) 
ISBN 978-952-03-1427-9 (pdf) 
ISSN 2489-9860 (print) 
ISSN 2490-0028 (pdf) 
http://urn.fi/URN:ISBN:978-952-03-1427-9 
 
 
PunaMusta Oy – Yliopistopaino 
Tampere 2020 
iii
ABSTRACT
Sarcoidosis is a granulomatous inflammatory disease that can affect any organ
system. It most often manifests in lungs and hilar lymph nodes. It is often
asymptomatic and has a benign prognosis. With a quarter of the patients, sarcoid
inflammation affects the heart and this cardiac involvement accounts for the
majority of sarcoidosis-related morbidity and mortality.
FDG-PET is a nuclear medicine imaging study with an ability to visualize
inflammatory foci. Lately, it has gained importance in the workup of cardiac
sarcoidosis.
One hundred thirty-seven PET studies performed in Tampere University Hospital
between August 2012 and September 2015 for patients suspected with cardiac
sarcoidosis were retrospectively analysed. With an aim to study the role of FDG-
PET in the workup of cardiac sarcoidosis, we examined the associations of PET-
findings and patient characteristics, PET-findings and ECG-parameters and the
association of PET-findings in the heart and metabolically active foci elsewhere in
the body. In addition, we assessed the prognostic role of PET.
Pathological cardiac PET-findings were found to be more frequent in female
patients and with those with a history of atrioventricular block. Right ventricular
uptake was also associated with a history of ventricular tachycardia. Pathological
cardiac PET findings also correlated to novel ECG parameters septal remodelling
and inferolateral remodelling in addition to widespread QRS fragmentation and left
anterior hemiblock. A biopsy sample indicating sarcoidosis was obtained more
frequently from patients with metabolically active foci outside of the heart.
Additionally, an association between right ventricular uptake and uptake in
mediastinal and hilar lymph nodes was observed. In our population, right
ventricular uptake and high total cardiac metabolic activity predicted adverse
cardiac events during follow-up.
Our study identified a group of patients, defined according to sex, medical history
and certain ECG parameters, who have a higher frequency of positive cardiac
findings in FDG-PET. The imaging study can be a useful tool in the workup of
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cardiac sarcoidosis as it can aid in the diagnosis by pointing targets for tissue
biopsy. Furthermore, certain findings could be considered as indicators for high
risk of cardiac events.
vTIIVISTELMÄ
Sarkoidoosi on tulehdussairaus joka voi esiintyä missä elimessä tahansa. Yleisimmin
se ilmenee keuhkoissa ja välikarsinan imusolmukkeissa. Sarkoidoosi on usein
oireeton sattumalöydös ja sen ennuste on suotuisa.
Sarkoidoosi voi kutienkin esiintyä sydänlihaksessa jopa neljänneksessä tapauksista.
Sydämessä esiintyvään tautimuotoon liittyy merkittävää sairastavuutta ja
kuolleisuutta.
FDG-PET on isotooppitutkimus, jolla voidaan kuvata elimistön metabolista
aktiivisuutta ja osoittaa muun muassa tulehdusprosessiin liittyvää korostunutta
sokeriaineenvaihduntaa.
Tätä väitöskirjatutkimusta varten uudelleenanalysoitiin 137 tehtyä FDG-PET
tutkimusta, jotka oli tehty elokuun Tampereen yliopistosairaalassa elokuun 2012 ja
syyskuun 2015 välillä sydänsarkoidoosiepäilyn vuoksi. Halusimme tutkia PET-
kuvauksen merkitystä potilailla, joilla epäiltiin sydämen sarkoidoosia. Vertasimme
PET-löydöksiä potilaiden perustietoihin, sairaushistoriaan ja EKG-löydöksiin.
Lisäksi tutkimme sydämen ja sydämen ulkopuolisten poikkeavien
aineenvaihduntafokusten suhdetta ja selvitimme PET-löydösten kykyä ennustaa
sydäntapahtumia.
Havaitsimme, että poikkeavia sydänlöydöksiä oli enemmän naisilla ja niillä joilla oli
sairaushistoriassa merkintä eteis-kammiokatkoksesta. Oikean kammion poikkeavia
muutoksia oli useammin potilailla, joilla oli ollut kammioperäisiä rytmihäiriöitä.
Poikkeavat sydänlöydökset olivat yleisempiä potilailla, joiden EKG:ssa oli
nähtävissä QRS-kompleksin fragmentaatiota useissa kytkennöissä, oikean
etuhaarakkeen katkos. Poikkeavat sydämen PET-löydökset liittyivät myös
väliseinän uudelleenmuovautumiseksi ja alaseinän uudelleenmuovautumiseksi
nimettyihin, hiljattain määriteltyihin EKG-muuttujiin. Sarkoidoosiin sopiva
kudosnäyte saatiin useammin potilailta, joilla nähtiin aineenvaihduntafokuksia
sydämen ulkopuolella. Sydämen ulkopuolisilla ja oikean kammion poikkeavilla
PET-löydöksillä havaittiin olevan yhteys. Oikean kammion poikkeavat löydökset ja
korkea sydämen kokonaisaineenvaihdunta-aktiivisuus ennustivat sydäntapahtumia.
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Tulosten perusteella FDG-PET on käyttökelpoinen tutkimus
sydänsarkoidoosiepäilyssä. Tunnistimme potilasryhmiä, joilla poikkeavan PET-
löydöksen todennäköisyys on korkea. Havaitsimme, että PET-tutkimus voi osoittaa
kohteita kudosnäytteen ottoon ja auttaa siten diagnoosiin pääsyssä. Lisäksi
havaitsimme tiettyjen PET-löydösten liittyvän suureen sydäntapahtumien riskiin,
mikä tulee ottaa huomioon potilaan hoidossa.
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1 INTRODUCTION
Cardiac involvement accounts for the majority of mortality and morbidity associated
with sarcoidosis.1 Besides cardiac involvement in systemic sarcoidosis, sarcoid
inflammation confined to heart has been recently recognized.2-6 Timely diagnosis of
cardiac sarcoidosis is important for appropriate medical treatment, but diagnosing
cardiac sarcoidosis remains difficult. The gold standard of diagnosis is verification
of granulomatous inflammation by endomyocardial biopsy, which has low
sensitivity. 7-9
FDG-PET is a nuclear imaging modality that is able to demonstrate inflammation
by tracer accumulation in cells with high glucose metabolism. Activated
inflammatory cells in sarcoid granulomas have elevated glucose metabolism,
demonstrated by FDG accumulation in PET-imaging.10-12
Multiple studies on the diagnostic performance of FDG-PET have been published
during the last decades and the latest meta-analysis was published in 2019. The
imaging and patient preparation protocols have been variable. Sarcoidosis is known
to have different disease course in different ethnic populations, making it uncertain
whether results on certain population are generalizable to other populations.13-15 A
major difficulty in all studies is the lack of reliable diagnostic gold standard.
Previous study on the epidemiology of cardiac sarcoidosis in Finland has
demonstrated the important role of FDG-PET in the diagnostic process. However,
the diagnostic and prognostic significance of different PET findings have not been
studied among Finnish population. The aim of my study was to investigate the
associations and clinical significance of different PET findings.
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2 LITERARY REVIEW
2.1 Pathology of sarcoidosis
Sarcoidosis is a multisystem inflammatory disease characterized by formation of
immunological granulomas in various organ systems. 16
The cause of the disease is unknown. Immunologically, sarcoidosis is an
exaggerated response to an external antigen. Genetic predisposition is thought to
account for a major part of disease suspectibility.17 Numerous gene loci have been
linked to sarcoidosis predisposition, each conferring a 1.1 to 1.8 times increased risk
compared to non-carriers.18-21
Several environmental pathogens and other antigens have been linked to
sarcoidosis. In addition, exposure to metal industry and insecticides have been linked
to elevated risk of sarcoidosis.22,23  Besides inorganic antigens, bacteria may trigger
sarcoid inflammation. There is evidence that mycobacteria and propionibacteria may
cause granuloma formation.24 These bacteria have features that allow them to reside
inside macrophages without being completely degraded. Signs of mycobacteria have
been identified in half of tissue biopsies obtained from sarcoid granulomas.25
Similarly, propionibacter DNA has been found.26
Immunologically, macrophages start the cascade that leads to the formation of a
granuloma. In patients with sarcoidosis, alveolar macrophages have the ability to
function as antigen presenting cells and triggering T-cell proliferation. Interestingly,
macrophages from healthy individuals down-regulate T-cell proliferation.27 Antigen
presenting ability of macrophages is linked to MCH-expression which in turn is
linked to genetic HLA-DR-subtypes that are known to affect the clinical course of
sarcoidosis.19 Activated macrophages secrete cytokines, notably TNF-ơ, triggering
the influx of TH1-cells. These in turn produce TNF-ơ, IL-1 and interferon that
further activate macrophages. Immune response is exaggerated because regulatory
T-cells are low in number and act ineffectively in patients with sarcoidosis.28
Epithelioid granuloma formation is a mean to insulate the undegradable parts of
antigen that triggered the inflammation. In some patients, the inflammation is later
17
downregulated by the formation of immunosuppressive cytokines.29 In others, the
persisting antigen leads to a chronic inflammation.
2.1.1 Pathophysiology and clinical presentation of cardiac sarcoidosis
When the heart is affected by sarcoidosis, noncaseating granulomas form in the
heart. Granulomas may form in any part of the heart but left ventricle is most often
affected. Histologically, cardiac sarcoidosis has three successive stages. The process
begins with edema followed by active granulomatous inflammation. These then lead
to fibrosis and cause scarring.30 Clinically, cardiac sarcoidosis most often causes
conduction abnormalities, tachyarrhythmias and cardiomyopathy. Less frequently
encountered manifestations include pericarditis, valvular pathologies due to direct
granuloma infiltration and ischemic presentation due to coronary arterial
granulomas.31  High-degree atrio-ventricular (AV) conduction block is the most
common clinical manifestation. In a population of young patients with advanced AV
block 25-34 % of the patients were later diagnosed with cardiac sarcoidosis.32,33
Ventricular tachycardias (VTs) may be the first manifestation of cardiac
sarcoidosis.34,35 In certain populations of patients with unexplained VT, 29 %  of
patients have had cardiac sarcoidosis.4 Cardiomyopathy with degraded left
ventricular function and clinical decompensation has been shown to indicate poor
prognosis.14
2.2 Epidemiology of sarcoidosis and cardiac involvement
Sarcoidosis generally has a widely varying prevalence of 4.7-64 in 100,000 and
incidence of 1.0 to 35.5 in 100,000 per annum in different populations. According
to an American study, women seem to be more affected, as the study suggests that
females were twice as likely as males to have sarcoidosis.13 Prevalence and incidence
figures are highest among populations in Northern Europe and lowest in Japan.15,36
Sarcoidosis presents most commonly in patients between 20-39 years of age and  the
incidence peaks at a different age in different populations. In African American
population, the disease often occurs later than in other populations and the disease
course is more often chronic.36 With Scandinavian and Japanese women the
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incidence curve has two peaks, the first one at 20 to 29 years and the second one at
65 to 69 years.37
Epidemiology of cardiac sarcoidosis is more uncertain. In autopsy studies, the
prevalence of cardiac involvement in patients with systemic sarcoidosis has been 25
%.38 Studying the epidemiology of cardiac sarcoidosis is complicated by difficulties
in diagnosing the disease. In post-mortem studies of patients with cardiac
sarcoidosis, less than half of the patients had signs of cardiac involvement during
their lifetime.39 In a nationwide Finnish study, the prevalence of biopsy-confirmed
cardiac sarcoidosis was 2.2 in 100,000.3 The prevalence has mostly been studied with
patients with systemic sarcoidosis. Prevalence figures of 1% to 26% have been
described, depending on diagnostic method and population.40,41 In a large American
cohort study, cardiac manifestation accounted for 31 % of hospitalizations due to
sarcoidosis.42
Lately, an isolated form of cardiac sarcoidosis has been recognized.2-6 The
frequency of isolated cardiac sarcoidosis is inadequately established due to
insensitivity of diagnostic criteria (discussed in the following chapter) to recognize
this form of the disease. The proportion of isolated form among sarcoidosis patients
has been reported to vary from 27 to 54 %.43 Kandolin et al found that isolated
cardiac sarcoidosis more often presented with decreased left ventricular ejection
fraction (LVEF) and was associated with poorer prognosis than cardiac involvement
in systemic sarcoidosis.3
2.3  Diagnosis of cardiac sarcoidosis
Currently, the diagnosis of cardiac sarcoidosis is based on two sets of criteria. The
most established criteria have been published by Japanese Ministry of Health and
Welfare first in 1993 and revised in 2006 and 2017 by Japanese circulatory society
(JCS).44-46 (tables 1-4). The other set of diagnostic criteria commonly used was
published by Heart Rhythm Society (HRS) in 2014 (table 5).47 According to both
criteria, there are two ways to diagnose cardiac sarcoidosis. The most robust
diagnosis is established by detecting non-caseating granulomas in endomyocardial
biopsy (EMB). Due to the patchy distribution of granulomatous inflammation in the
heart, the sensitivity of EMB has been reported to be as low as 19-30 %7-9. The
diagnosis of “probable cardiac sarcoidosis” can be established in patients with
biopsy-proven systemic sarcoidosis when a certain set of clinical and imaging criteria
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are met. These criteria differ slightly between JMHW/JCS and HRS. The latest JCS
guidelines also include diagnostic criteria for isolated cardiac sarcoidosis (table 4).
Table 1.  JCS 2017 General Criteria for diagnosing cardiac sarcoidosis 46
1) Histological diagnosis group (those with positive myocardial biopsy findings)
Cardiac sarcoidosis is diagnosed histologically when endomyocardial biopsy or
surgical specimens demonstrate non-caseating epithelioid granuloma
2) Clinical diagnosis group (those with negative myocardial biopsy findings or
those not undergoing myocardial biopsy)
The patient is clinically diagnosed as having sarcoidosis when epithelioid
granulomas are found in organs other than the heart, and clinical findings
strongly suggestive of the above-mentioned cardiac involvement (Table 2) are
present;
or when the patient shows clinical findings strongly suggestive of pulmonary or
ophthalmic sarcoidosis; at least two of the five characteristic laboratory findings
of sarcoidosis (Table 3); and clinical findings strongly suggest the above-
mentioned cardiac involvement (Table 2)
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Table 2. Criteria for cardiac involvement in sarcoidosis (JCS 2017)46
Major criteria:
a) High-grade atrioventricular block (including complete atrioventricular block) or
fatal ventricular arrhythmia (e. g., sustained ventricular tachycardia and ventricular
fibrillation)
b) Basal thinning of the ventricular septum or abnormal ventricular wall anatomy
(ventricular aneurysm, thinning of the middle or upper ventricular septum, regional
ventricular wall thickening)
c) Left ventricular contractile dysfunction
(left ventricular ejection fraction less than 50%)
d) 67Ga citrate scintigraphy or 18F-FDG PET reveals abnormally high tracer
accumulation
e) Gadolinium-enhanced MRI reveals delayed contrast enhancement of the
myocardium
Minor criteria:
f) Abnormal ECG findings: Ventricular arrhythmias (non-sustained ventricular
tachycardia, multifocal or frequent premature ventricular contractions), bundle
branch block, axis deviation, or abnormal Q waves
g) Perfusion defects on myocardial perfusion scintigraphy (SPECT)
h) Endomyocardial biopsy: Monocyte infiltration and moderate or severe myocardial
interstitial fibrosis
Clinical findings that satisfy the following 1) or 2) strongly suggest the presence of
cardiac involvement.
 1) Two or more of the five major criteria (a) to (e) are satisfied
 2) One of the five major criteria (a) to (e) and two or more of the three minor
criteria (f) to (h) are satisfied.
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Table 3. Characteristic imaging and laboratory findings of sarcoidosis. (Japan Society of
Sarcoidosis and other Granulomatous Disorders. 2015) 46
1) Bilateral hilar lymphadenopathy
2) High serum angiotensin-converting enzyme (ACE) activity or elevated serum
lysozyme levels
3) High serum soluble interleukin-2 receptor (sIL-2R) levels
4) Significant tracer accumulation in 67Ga citrate scintigraphy or 18F-FDG PET
5) A high percentage of lymphocytes with a CD4/CD8 ratio of >3.5 in BAL fluid
Clinical diagnosis of sarcoidosis is supported when at least two of the above five
characteristic findings are observed
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Table 4. Diagnostic criteria for isolated cardiac sarcoidosis (JCS 2017)46
1. No clinical findings characteristic of sarcoidosis are observed in any organs
other than the heart. (The patient should be examined in detail for respiratory,
ophthalmic, and skin involvements of sarcoidosis. When the patient is
symptomatic, other etiologies that can affect the corresponding organs must be
ruled out.)
2. 67Ga scintigraphy or 18F-FDG PET reveals no abnormal tracer accumulation
in any organs other than the heart.
3. A chest CT scan reveals no shadow along the lymphatic tracts in the lungs or
no hilar and mediastinal lymphadenopathy (minor axis > 10 mm).
1) Histological diagnosis group Isolated cardiac sarcoidosis is diagnosed
histologically when endomyocardial biopsy or surgical specimens demonstrate
non-caseating epithelioid granulomas.
2) Clinical diagnosis group Isolated cardiac sarcoidosis is diagnosed clinically when
the criterion (d) and at least three other criteria of the major criteria (a)-(e) are
satisfied (Table 2)
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Table 5.  Heart Rhythm Society expert consensus recommendation on criteria for the diagnosis
of cardiac sarcoidosis47
There are 2 pathways to a diagnosis of Cardiac Sarcoidosis:
1. Histological Diagnosis from Myocardial Tissue CS is diagnosed in the presence
of non-caseating granuloma on histological examination of myocardial tissue with
no alternative cause identified (including negative organismal stains if applicable).
2. Clinical Diagnosis from Invasive and Non-Invasive Studies: It is probable* that
there is CS if:
a) There is a histological diagnosis of extra-cardiac sarcoidosis and
b) One or more of following is present
Steroid +/- immunosuppressant responsive cardiomyopathy or heart block
Unexplained reduced LVEF (40%)
Unexplained sustained (spontaneous or induced) VT
Mobitz type II 2nd degree heart block or 3rd degree heart block
Patchy uptake on dedicated cardiac PET (in a pattern consistent with CS)
Late Gadolinium Enhancement on CMR (in a pattern consistent with CS) Positive
gallium uptake (in a pattern consistent with CS)
c) Other causes for the cardiac manifestation(s) have been reasonably excluded
*In general, ‘probable involvement’ is considered adequate to establish a clinical
diagnosis of CS.33
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2.4 Prognosis and management of sarcoidosis
2.4.1 Prognosis of sarcoidosis is largely dependent on cardiac involvement
Sarcoidosis without cardiac involvement has a benign prognosis and often the
inflammatory process resolves without treatment. In case of cardiac involvement,
however, the prognosis is less favorable. Cardiac involvement accounts for the
largest proportion of sarcoidosis-related deaths.1
2.4.2 Prognosis of CS
In the early prognostic studies from the 1970’s, CS resulted in death in two years.48
In the era of modern diagnostic tools, such as effective anti-inflammatory treatment,
implantable cardioverter-defibrillators and cardiac transplantation surgery, the
prognosis is far better:. In a nationwide Finnish study of 110 patients, the mortality
rate was 9 % during follow up of 79 months (1.4 annually).3 Another Finnish study
compared the clinical outcome in patients with EMB-verified cardiac sarcoidosis to
that of patients with extracardiac sarcoidosis and imaging findings suggesting cardiac
involvement. Of the 149 patients, 34 suffered sudden cardiac death, aborted cardiac
death or underwent heart transplantation. There was no significant prognostic
difference between EMB-verified and other patients.49
Decreased left ventricular ejection fraction has been shown to indicate poor
prognosis.14 Chiu et al found that all patients with normal LVEF were alive at 10
years compared to only 19 % of those with LVEF < 35 %.50 In the study of Yazaki
et al, history of ventricular tachycardia, in addition to LVEF, New York Heart
Association class, left ventricular end diastolic diameter indicated high risk of cardiac
events. In addition, Low LVEF predicted appropriate implantable cardioverter-
defibrillator (ICD) therapies in three studies.51-53
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2.4.3 Treatment of cardiac sarcoidosis
Treatment of CS is based on immunosuppressive medication intended to prevent
further damage to myocardium caused by persisting active inflammation. Other
components of the treatment are aimed to specific manifestations: antiarrhythmic
medications, VT-ablation and ICD implantation for ventricular arrhythmias and
pacemaker therapy for conduction abnormalities. Guidelines on the treatment of CS
have been published by the heart rhythm society in 2014.47
2.4.3.1 Immunosuppression
Immunosuppression is widely used to treat CS but the scientific literature on its
efficacy is scarce and somewhat mixed. In a Canadian literary review, corticosteroid
treatment improved LVEF in patients who had moderately decreased left ventricular
end-diastolic diameter (LVEDD) but not in those with severely decreased left
ventricular function.54 However, Kandolin et al found that LVEF improved with
corticosteroid treatment in those with LVEF < 35 % but not in those with less
severely depressed left ventricular function.3 Padala et al showed in their study that
early initiation of corticosteroid therapy results in recovery of LVEF, AV conduction
and resolution of VTs more often that delayed corticosteroid treatment.55 In  a
Canadian review, Sadek et al summarize six studies on the effect of corticosteroid
treatment on AV- conduction. High-degree AV-block resolved in 47 % of the 57
patients treated with corticosteroids compared to none of the 16 untreated patients.
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2.4.3.2 Antiarrythmic treatment and catheter ablation for VTs
Amiodarone and sotalol are the antiarrhythmic drugs most often used to treat VTs
in CS. However, there is no evidence for benefit on long-term outcome.56 There are
few studies on the benefit of catheter ablation on VTs in patients with CS. The
populations in the studies have been small and results mixed as other study found a
favorable effect on VT burden whereas in the other study VTs recurred in majority
of patients.57,58
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2.4.3.3 Pacemaker and ICD-implantation
Heart rhythm society recommends implantation of pacemaker in CS patients with
2nd or 3rd degree AV block. Even if AV-conduction may recover with corticosteroid
treatment as described earlier, the recovery is unpredictable and AV-conduction may
degrade again after the initial recovery. Furthermore, it is recommended that ICD
should be implanted to patients with indication for permanent pacing as patients
with CS have an elevated risk of life-threatening ventricular arrhythmias. ICD-
implantation is also recommended in patients with spontaneous sustained ventricular
tachycardias and in those with LVEF<35 %. It is also considered useful with patients
who have experienced a syncope of > 30 seconds which is believed to be of
arrhythmic origin or who have inducible ventricular tachycardias of > 30 seconds in
electrophysiological study.47
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2.5 Use of electrocardiography and imaging modalities in the
diagnostics of CS
2.5.1 Electrocardiography
Electrocardiographic abnormalities are detected in up to 50 % of patients with
systemic sarcoidosis.14 These abnormalities include disturbances in rhythm,
conduction and repolarization.59 These findings are often asymptomatic.60  Even
though standard ECG is recommended in the routine evaluation of patients with
sarcoidosis, the abnormalities mentioned previously are nonspecific. It has been
shown that standard ECG has low accuracy in detecting CS.61 Ambulatory Holter-
recording improves accuracy as it was found to have sensitivity and specificity of
67% and 62%, respectfully, when more than 100 ventricular beats in 24 hour
recording was considered pathological.62 Lately, new parameters based on QRS
fragmentation have been developed for ECG analysis and these have been shown to
associate with different structural heart diseases, including cardiac sarcoidosis.63-66
These results are considered preliminary and remain to be confirmed in future
studies.
2.5.2 Echocardiography
Echocardiography is usually the first imaging study for patients suspected of having
cardiac sarcoidosis. Echocardiography is easily available and involves no ionizing
radiation. Common clinical presentations of cardiac sarcoidosis (conduction
abnormalities, tachyarrhythmias and cardiomyopathy) can be caused by multitude of
cardiovascular pathologies, many of which are detected in echocardiography.
Echocardiographic findings in CS are variable and often unspecific. The
echocardiographic abnormalities in CS include regional wall motion abnormalities,
dilated left ventricle, ventricular aneurysms, systolic or diastolic dysfunction, septal
thinning or thickening, valvular dysfunction and pericardial effusion. Studies on the
prevalence of these findings have been conducted on relatively small patient
populations. The most frequent abnormal findings have been left ventricular (LV)
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dysfunction, wall motion abnormalities and septal thinning. Of these, septal thinning
has been recognized as the most specific for CS..67-70 If there is clinical suspicion of
CS based on findings described above, further studies with other imaging modalities
(discussed below) are warranted.
If the diagnosis of CS has been established, LVEF determined by
echocardiography is a strong prognostic factor alongside left ventricle end-diastolic
diameter.14,50 As CS is a possibly progressive condition, the patients should be
followed up to detect possible deterioration of LV function that warrants for
escalation of immunosuppressive treatment. Resolution of echocardiographic
abnormalities by treatment with corticosteroids has been described.71
2.5.3 Magnetic resonance imaging
There is strong evidence for the utility of cardiac magnetic resonance (CMR) imaging
in diagnosing CS. MRI imaging is based on magnetic resonance in tissue. CMR can
be used to assess possible edema and myocardial fibrosis and to determine
ventricular function. Edema is a hallmark of acute inflammation, whereas fibrosis
due to scarring is a later manifestation in cardiac sarcoid disease. Ventricular function
is a strong prognostic factor as already discussed in the previous chapter.
Acute inflammation in myocardial tissue causes edema e.g. increases the amount
of extracellular fluid. In CMR, T1 and T2 will increase in proportion to the amount
of extracellular water.72 Edema can also cause focal myocardial thickening and early
gadolinium enhancement.73,74 In the case of extensive infiltration by sarcoid,
confluent granulomas can be visualized in T2-images as signal-intense ring-shaped
areas in myocardium. The central portion with low signal intensity represents scar
that is surrounded by edematous inflammatory tissue.
Late gadolinium enhancement (to be discussed later) is considered the most
specific diagnostic sign in suspected CS. However, Crouser et al found that assessing
T2-weighed images improved the detection rate of cardiac involvement in patients
with proven sarcoidosis.75 In a follow up study, they found a reduction in T2 signal
in patients successfully treated with anti-inflammatory medication.76 The population
in the studies was small and the results have to be confirmed in larger populations.
However, a non-ionizing imaging modality that could be used in assessing the
efficacy of anti-inflammatory medication would be desirable.
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The role of late gadolinium enhancement (LGE) as diagnostic marker has been
studied extensively. The most typical site for LGE in cardiac sarcoidosis is mid-
myocardial and subepicardial spaces in basal septum and inferolateral wall.77 LGE is
considered to represent fibrotic scar tissue but it can also result from the increase of
extracellular space in edema. Thus in some cases, LGE can subside with anti-
inflammatory treatment.78 Smedma et al studied the accuracy of LGE compared to
JMHW criteria in 58 patients with systemic sarcoidosis. In this population, sensitivity
was 100 % and specificity 78 %.79 In later studies, it has been shown that LGE
predicts adverse cardiac events twice better than fulfillment of JMHW criteria. In
sarcoidosis patients with suspected cardiac involvement, LGE signified nine-fold
risk of adverse cardiac events and 11.5 fold risk of cardiac death.113 Greulich et al
later found even higher figures of hazard ratio (HR) for cardiac events and death
(31.6 and 33.9, respectively) in a population of 155 consecutive sarcoidosis patients
with suspected cardiac involvement.80 In 2016, a meta-analysis on prognostic value
of LGE was published by Coleman et al. in which 10 studies involving 760 patients
were included. The investigators used composite arrhythmic outcome (ventricular
arrhythmia, implantable cardioverter-defibrillator shock and cardiac death) and all-
cause mortality as endpoints. Odds ratio for all-cause mortality was 3.06 (p=0.03)
and 10.74 (p<0.001) for composite outcome. In a recently published study,
Smedema et al showed that LGE in right ventricle or in both ventricles signifies
especially high risk of cardiac events.81 However, several studies have shown that
LGE can be found in sarcoidosis patients without any signs or symptoms of cardiac
involvement. In these patients, there is no elevated risk of adverse cardiac events.82,83
This highlights the importance of interpreting different imaging findings as a part of
the clinical context.
2.5.4 Myocardial perfusion imaging
Granulomatous inflammation in CS may in some patients lead to myocardial fibrosis.
This in turn causes perfusion defects that can be detected in myocardial perfusion
imaging. There are few studies on the utility of myocardial perfusion imaging
(without combined FDG-PET) in CS. Le Guludec et al studied the utility of
Thallium and Tc 99m sestamibi SPECT in 37 patients with known CS.84 Sestamibi
was found to be more sensitive as 24 of the 37 patients showed perfusion defects
compared to only 17 in thallium imaging. Reduction in the size of the defects in
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dipyridamole images was correlated with improvement in follow up imaging after
corticosteroid therapy. A Japanese group studied sestamibi/tetrofosmin SPECT in
cardiac (n=6) and non-cardiac (n=10) patients.85 LV and RV defects were found in
5/16 and 14/16 patients, respectively. Patients with CS had more defects than those
with non-cardiac sarcoidosis. LV defects were linked to AV block and heart failure
and RV defects with arrhythmias of RV origin. There is also an interesting study on
the ability of the washout of 99mTc-tetrofosmin to predict treatment response to
corticosteroids.86 Early (30 min) and delayed (3 h) tetrofosmin perfusion imaging
was performed in ten patients with CS before and after steroid therapy. Washout
was defined as difference between defect scores in early and delayed images, and it
was considered a marker of tracer redistribution. Washout was detected in six out of
ten patients. Washout was found to be correlated to LVEF recovery with
corticosteroid therapy.
2.5.5 Positron emission tomography
2.5.5.1 Basic concept of FDG-PET
Positron emission tomography (PET) is an imaging modality utilizing tracers labelled
with positron-emitting isotopes. The most commonly used tracer is ¹΄F-
fluorodeoxyglucose (¹΄F-FDG), a glucose analogue. FDG uptake is regulated by
glucose transporters.10 FDG imaging is widely utilized in oncology to demonstrate
metabolically active malignant tissue with increased number of glucose transporters.
Similarly, activated inflammatory cells have increased number of active glucose
transporters.11,12 FDG-PET has been successfully utilized in variety of infectious and
inflammatory conditions, e.g. vasculitis, infections of joint or vascular prostheses,
fever of unknown origin, suspected postoperative infections and sarcoidosis.
2.5.5.2 Suggested indications for FDG-PET in suspected cardiac sarcoidosis
In 2017 a joint consensus statement on the role of FDG-PET in the detection and
monitoring of CS was published by Society of nuclear medicine and American
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society of nuclear cardiology.87 This document provides suggested indications for
FDG-PET in four different clinical situations.
1) In patients with known systemic sarcoidosis, FDG-PET is indicated if there
are findings suggestive of CS in ECG (LBBB, RBBB, Q-waves in>1 leads),
ambulatory Holter monitoring (VT or NSVT), echocardiography (wall
motion abnormality, aneurysm, basal septum thinning or LVEF <50%) or
cardiac MRI. FDG-PET is also indicated in patients with palpitations or
syncope.
2) Young (<60 y) patients with unexplained II or III degree AV-conduction
block.
3) Patients with idiopathic sustained VT that does not fulfill the criteria for
typical outflow tract or fascicular VT and that is not secondary to other
known heart disease.
4) as a follow treatment response or identify reactivation in patients with known
CS
2.5.5.3 Strategies to reduce physiological FDG-uptake in the myocardium
In the case of cardiac sarcoidosis, PET-imaging is complicated by variable and
unpredictable physiological FDG-uptake in the myocardium. In the fasting state,
free fatty acids are the primary energy source in the myocardium.88  As a meal triggers
the secretion of insulin, myocardial tissue switches to utilizing glucose as an energy
source.89 However, even after fasting for 4 to 6 hours myocardium may demonstrate
physiological uptake due to activity of certain glucose transporter subtypes.90
This physiological uptake can vary in location and over time even in the same
patient.91 It has been shown that this physiological uptake is not dependent on
fasting blood level glucose, fasting time or the age of the patient.92,93
Several strategies have been developed to minimize the physiological myocardial
FDG uptake. These strategies are based on prolonged fasting, carbohydrate-
restricted diet prior to imaging and inducing hepatic lipases with non-fractioned
heparin.
Prolonged fasting >18 h has been shown to result in reduced myocardial uptake
compared to standard fast of up to 6 hours.94 However, even after prolonged fast
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up to 38 % of patients show myocardial FDG uptake.95 Besides, patient adherence
to long fasting could be questionable.
Several studies have proven the effectiveness of carbohydrate-restricted, high-fat
diet. Williams et al found that patient who consumed high fat low carbohydrate diets
prior to imaging had lower myocardial maximum standardized uptake values
(SUVmax) compared to those who fasted according to standard protocols.96 The
results have been verified by later studies.97,98 Despite optimal dietary preparation up
to 20 % of patients show physiological myocardial FDG-uptake.94
Administration of unfractionated heparin in low doses triggers lipolysis and
increases the level of free fatty acids in circulation.99 This will theoretically aid in
switching myocardial cells to utilize fatty acids instead of glucose, thus reducing
FDG uptake. Indeed, Masuda et al show in a relatively large population the
additional effect of administering 50 IU/kg unfractionated heparin 15 minutes prior
to FDG compared with prolonged fasting alone.95
Combining different strategies has been shown to be effective by Manabe et al:
low-carbohydrate meal prior to 18 h fast and injection of unfractionated heparin
prior to FDG resulted in complete reduction of myocardial FDG-uptake in 100 %
of 24 patients.100
An effective strategy to reduce physiological myocardial uptake is essential when
imaging patients with suspected CS. In some cases, physiological uptake may cause
a false positive finding. Even when the physician interpreting the images is aware of
physiological uptake phenomenon, it may mask pathological uptake and cause false
negative findings. Furthermore, calculating quantitative parameters is unreliable if
there is extensive physiological uptake. An expert consensus by Society of nuclear
medicine and molecular imaging and American society of nuclear cardiology
recommends high-fat-low-carbohydrate diet for the day preceding FDG-PET
combined to a 4-12 h fast prior to FDG-injection. Intravenous heparin (50 IU/kg
15 minutes before FDG-injection) may be used although its role in suppressing
physiological myocardial uptake is considered uncertain.87
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2.5.5.4 Interpretation of FDG-PET images
To achieve accurate diagnosis FDG-PET imaging is usually performed in
combination with myocardial perfusion imaging. This strategy allows detecting both
active inflammation (FDG-PET) and myocardial scars (perfusion defects).101 FDG-
uptake pattern has been described in different ways but the most commonly used
classification of uptake pattern was introduced by Ishimaru et al.102 His group
describe four different FDG-uptake patterns in the myocardium: no uptake, diffuse
uptake, focal uptake and focal on diffuse pattern. The first two patterns are
considered physiological and the two latter patterns are considered to represent
sarcoid inflammation.
FDG accumulates only in active inflammatory process whereas fibrous scar
caused by spontaneously subdued sarcoid inflammation is metabolically inactive. As
mentioned previously, FDG-PET is often performed in combination with perfusion
imaging.101 Perfusion imaging can be performed using sestamibi-scintigraphy or
PET-based imaging with 13N-NH3, 82Rb or O2 water. The prevalence of perfusion
defects in sarcoidosis patients suspected for cardiac involvement has ranged from 44
% to 76 %.103-105 Populations in the studies have been relatively small and different
perfusion imaging modalities have been used. The highest frequency for perfusion
defects was found in a population of patients fulfilling the JMHW criteria and imaged
with 13N-NH3-PET.
Combining the results of FDG-PET and perfusion imaging allows recognizing
different stages of CS. In a normal case, there is no FDG-accumulation in
myocardium and the resting perfusion is normal. As a physiological variation, diffuse
low-grade FDG-uptake may be seen and in combination with normal resting
perfusion, this is considered a normal finding.102 In the early stage, there is active
focal uptake of FDG representing active inflammation in granulomas. At this stage,
resting perfusion may be normal or there may be defects due to compression of
vascular structures by the inflammatory granulomas. The latter case is called a
mismatch pattern. Coronary artery disease (CAD) has been ruled out in most
patients referred to PET-imaging for suspected cardiac sarcoidosis but it has to be
kept in mind that hibernating myocardium in CAD could present a similar finding.106
A scar without active inflammation can be seen in a later stage. Okamura et al
proposed a pathological classification in to five categories based on FDG and
perfusion findings. “Normal” has normal perfusion and no pathological FDG
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uptake, “Early Stage” has no perfusion defect but has pathological FDG uptake,
“Progressive Inflammatory Stage” has mild perfusion defect(s) and pathological
FDG uptake, “Peak Active Stage with moderate perfusion defect and increased
FDG uptake, “Progressive Myocardial Impairment Stage” that has severe
perfusion defects combined to pathological FDG uptake, and finally “Fibrosis
Stage” of severe perfusion defect with minimal or no FDG uptake. The different
findings are depicted in figure 1, reproduced with permission from a review by
Blankstein et al.107
Figure 1. Different stages of CS by combination of FDG-PET and perfusion imaging (Reproduced
from Blancstein et al)
2.5.5.5 Whole-body imaging
In addition to demonstrating active inflammation in the heart, FDG-PET may show
active foci elsewhere in the body. As discussed above, sarcoidosis may manifest in
any organ or in different organs simultaneously.108 When FDG-PET imaging is
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performed for suspicion of CS, the imaging usually covers the area of thorax from
the level of clavicles to below the diaphragm. According to an American consensus
statement, the imaging should cover thorax, liver and spleen to detect possible
extracardiac uptake indicating systemic sarcoidosis.87 Diagnosis of CS warrants for
histological verification of sarcoidosis and EMB is known to be insensitive. Pointing
out active inflammation in extracardiac sites is thus valuable. In a Finnish study
involving 110 patients with CS, 50 % were diagnosed by EMB and the other half by
positive biopsy from an extracardiac site.3 To note, 65 % of the 110 patients had no
signs or symptoms of extracardiac disease but 71 % of these patients had active
mediastinal lymph nodes. In another study, Ishiyama et al detected extracardiac
FDG-foci in 81 % of patients with active CS. The most common sites were lymph
nodes (38 %), liver (25 %), lung (19 %) and bone marrow (19 %).109 It has also been
shown that in large proportion of CS-patients the FDG accumulation in mediastinal
lymph nodes is due to sarcoid inflammation.110
On the other hand, Blankstein et al found no association between pathological
cardiac findings and active extracardiac disease in 118 patients suspected for CS. In
this study, only 27 % of patients with pathological cardiac finding had extracardiac
foci.111 However, cases considered to have pathological cardiac finding also included
patients with perfusion defect only. These cases possibly represent late-stage cardiac
sarcoidosis in which the inflammatory process is subdued and this may explain the
lack of association demonstrated in other studies.
In 2017, Patel et al investigated whether there is an association between
extrathoracic and cardiac findings in 191 FDG-PET-studies performed to
sarcoidosis patients to evaluate possible cardiac involvement. Ten percent of the
patients showed pathological cardiac FDG-uptake and 40 % these showed
extrathoracic foci. The frequency of extrathoracic active sites was similar in the 171
patients with normal cardiac finding as 34 % of them had pathological FDG-uptake
outside thorax. The most common sites for active inflammation were lymph nodes,
liver, spleen and bone.112 These findings suggest that when performing FDG-PET
patients with known sarcoidosis it might be advisable to cover the whole body
instead of only thorax and upper abdomen to show all active disease.
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2.5.5.6 Diagnostic performance of FDG-PET in cardiac sarcoidosis
FDG-PET was first recognized as a potential tool in diagnosing cardiac sarcoidosis
in the early 2000’s. Mainly Japanese groups were inspired by studies that had shown
FDG-uptake in hilar and mediastinal lymph nodes in patients with sarcoidosis.113,114
The first known study was published by Yamagishi et al in 2003. They compared
FDG-PET + PET-perfusion study to Tl perfusion study + Ga-scintigraphy in 17
patients fulfilling the diagnostic criteria for CS. They showed the superior sensitivity
of the PET-studies and the reduction of FDG-uptake with anti-inflammatory
medication in a follow-up imaging.103 Other studies have later confirmed the results,
which were summarized in a meta-analysis on diagnostic performance of FDG-
PET.115 Seven studies involving 164 patients were included in the meta-analysis. The
inclusion criteria for patients was a prior diagnosis of sarcoidosis and fulfillment of
JMHW diagnostic criteria for CS or a strong clinical suspicion in some studies.
Reported sensitivity in the studies ranged 79–100 % and specificity ranged 38-89 %.
The overall pooled sensitivity and specificity were 89 % and 78 %, respectively.
However, studies reporting significantly lower sensitivity figures down to 34 % have
been published.116-119
Using quantitative methods to improve diagnostic accuracy has been studied.
Yokoyama has reported sensitivity and specificity of 97 % and 84 %, respectively,
using a SUVmax cut-off value 4.0.120 A recent study used dynamic FDG-PET and
coefficient of variation in myocardial glucose influx reaching sensitivity and
specificity of 100 % and 91 %, respectively, against JMHW criteria.
However, determining the true sensitivity and specificity of any imaging study is
complicated by lack of good gold standard for diagnosis: Patel et al investigated the
sensitivity of CMR and JMHW using follow up data as gold standard. They
concluded that CMR identified cardiac involvement more often than JMHW criteria
and follow up EMB data support the idea that the identified cases represent true
sarcoid involvement in the myocardium.121
There are only few studies comparing the diagnostic accuracy of FDG-PET and
CMR. In 2008, Ohira et al found slightly better sensitivity for FDG-PET compared
to CMR (88 % and 75 %, respectively). However, FDG-PET had significantly lower
specificity.122 In another study, the imaging modalities were compared in patients
with conduction system disease due to sarcoidosis. The results showed that CMR
more often identified myocardial damage in patients with mild chronic conduction
system disease whereas PET was more sensitive in patients with acute high-degree
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AV-block.123 This finding demonstrates the difference in the rationale of the imaging
methods: LGE in MRI detects scars left by the inflammatory process whereas PET
shows acute inflammation.
PET has also been studied in patients presenting with common symptoms of
cardiac sarcoidosis, namely AV-block and ventricular tachycardia. Manabe et al
found an association between advanced AV-block and pathological septal FDG-
uptake.124 In another study of cardiomyopathy patients with ventricular arrhythmias,
49 % of the patients had pathological myocardial FDG-uptake and 36 % of those
were later diagnosed to have CS.125 Nery et al studied a small population of patients
with monomorphic VT. They found that 6 out of 15 patients had pathological
myocardial FDG-uptake and four were later diagnosed to have CS. Drawing from
the findings discussed above, the SNMMI-ASNC consensus statement recommends
cardiac PET/CT imaging in case of unexplained AV-block in patients under 60 years
of age and in patients with idiopathic sustained VT.87
After the publication of previous meta-analysis in 2012, more studies have been
published. A new meta-analysis including 17 studies and 891 patients was published
in the beginning of 2019.121,126 All studies used JMHW criteria as a gold standard.
Sensitivity and specificity were 84 % and 83 %, respectively. The patient preparation
protocols ranged from none to high-fat-low-carb diet and unfractionated heparin.
As a slight surprise, in the included studies the patient preparation protocol did not
significantly affect the diagnostic accuracy. The addition of myocardial perfusion
imaging (MPI) tended to increase accuracy although the difference was not
statistically significant.
To summarize, studying the accuracy of FDG-PET in sarcoidosis is complicated
by lack of definite gold standard for diagnosis. JMHW criteria are most commonly
used but the shortcoming of the criteria is. During the last 10 years FDG-PET has
become an important imaging modality in suspected CS. It may directly demonstrate
inflammatory findings in myocardium to guide EMB, which is the only definite mean
to diagnose truly isolated CS. On the other hand, EMB and the risks involved can
be avoided in some cases by obtaining the biopsy from an extracardiac inflammatory
site if there is enough support for the diagnosis of CS from imaging and other cardiac
studies. The adequacy of the latter strategy finds support in a recently published
study by Simonen et al. The prognosis of EMB-verified absolute CS was compared
to probable CS diagnosed by combining sarcoidosis verification from an extracardiac
biopsy to cardiac findings fulfilling the diagnostic criteria discussed in chapter 1.3.
The results show that the 5-year survival was comparable in the different diagnosis
groups.49 However, the authors point out that EMB is still necessary to diagnose
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truly isolated CS and to differentiate CS from other inflammatory cardiomyopathies
such as giant cell myocarditis.
2.5.5.7 Prognostic performance of FDG-PET
During the last 10 years, the data supporting important prognostic role of PET in
suspected CS has been increasing. One of the most often cited article was published
in 2014 by Blankstein et al. They studied the prognostic role of FDG-PET in 118
patients with suspected CS. They found that the patients with pathological FDG-
uptake and/or perfusion defects had annual rate of tachycardia or death more than
four times higher than in those with no pathological imaging findings, even after
adjusting for diagnosis of CS according to JMHW criteria. Pathological uptake in the
right ventricle increased the risk even further.111 In a relatively small population of
36 patients, Ahmadian et al quantified metabolic volume intensity (total cardiac
metabolic activity tCMA) from average SUVmax in the heart and the volume of
pathological metabolic activity. They found that tCMA was an independent predictor
of adverse cardiac events.127
Prognostic potential of FDG-PET and CMR have been compared in a couple of
studies. Bravo et al concluded that pathological findings in PET did not predict
events when adjusted for LGE in CMR128. In another recent study investigating
prognostic performance of combined cardiac PET/MR, LGE was found to be the
best predictor of adverse events. However, pathological metabolic findings
significantly increased the event rate during follow-up. Pathological right ventricular
FDG-uptake was also found to be predictive of events after adjusting for baseline
left ventricular ejection fraction.129
A recent study investigated the prognostic value of quantitative PET and
perfusion imaging in 203 patients. They used 17-segment model to assess perfusion
and metabolism and quantified the heterogeneity of metabolism using coefficient of
variation. During the follow-up of 1.8 years, 63 patients developed adverse cardiac
event defined as defibrillation due to arrhythmia, heart transplant or death. In a
multivariate model coefficient of variation in metabolism and summed score of
mismatch defects predicted adverse events.130 Flores et al investigated whether
quantitative metabolic activity and its localization could predict adverse events. The
results in 67 patients show that SUVmax and SUVmean especially in the basal
segments of left ventricle were predictive of adverse cardiac events.131 It  has  also
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been shown that SUVmax over all sarcoidosis-involved organs (not only heart)
predict response to oral corticosteroids.109 Muser et al studied the prognostic value
of serial FDG-imaging during anti-inflammatory treatment. They calculated the
volume-intensity product in cardiac lesion (lesion metabolic activity LMA) and used
it to assess treatment response. Adverse cardiac events were significantly more
common in the patient with no reduction in LMA.132
2.5.6 Imaging of CS with somatostatin receptor binding PET-tracers
Sarcoid granulomas have an abundance of inflammatory cells expressing
somatostatin receptors (SSTRs) on their surface. Macrophages, giant cells and
epithelioid cells found in sarcoid granulomas express SSTR subtype II.133 This
receptor can be targeted by Ga68-labelled PET tracers DOTANOC (Ga-DOTA-
NaI-octreotide), DOTATATE (DOTA-DPhe-Tyr3-octreotate) and DOTATOC
(DOTA-D-Phe-Tyr-octreotide).
Ga-DOTA-tracers have been used for oncological indications for years. Lately,
they have been shown to be promising in the imaging of cardiac sarcoidosis.134
Compared to FDG-PET, Ga-DOTA tracers benefit from the absence of
physiological uptake in the myocardium as SSTRs are not expressed on the cells of
healthy myocardium.
The scientific evidence thus far is based on a few relatively small studies but is
promising. Nobashi et al found that Ga68-Dotatoc-PET was positive in 19/20
patients with systemic sarcoidosis and showed more active lesions than Ga-
Scintigraphy.135 Lapa et al compared Ga-Dotatoc and CMR in 15 patients with
systemic CS and a suspicion of cardiac involvement. SSTR-PET was positive in
seven patients and CMR in ten patients. Two of the PET-/CMR+ patients were
considered by the investigators as probable false positives as they showed no clinical
signs of active cardiac inflammation in the follow up. The authors conclude that
detecting CS by SSTR-PET is feasible.136  Gromsen et al have compared FDG-PET
and Ga-DOTANOC-PET in 19 patients with suspected CS. Only three were finally
diagnosed with CS but the results highlighted the unspecific nature of FDG-PET
imaging as 11/19 of the FDG-PET studies were inconclusive compared to none of
SSTR-PET studies. FDG-PET had a diagnostic accuracy of 79 % compared to 100
% of SSTR-PET. The authors conclude that FDG-PET has relatively low diagnostic
accuracy and SSTR-PET is a promising alternative.134
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2.5.7 Focus on the right ventricle
Right ventricular LGE or FDG-uptake has been the focus only in few studies.
However, the evidence exists for the importance of right ventricular findings on
diagnosis and prognosis of CS.
On the diagnostic aspect, Omote et al studied the association of EMB findings
and right ventricular (RV) uptake in FDG-PET. Of the 28 patients twelve (43 %)
had pathological RV-uptake. EMB was positive in 42 % of the patients with RV-
uptake but only in 6 % of those with no RV-uptake. They also followed the patients
for 42 months on average and found that those with RV-uptake had more adverse
cardiac events.137 Earlier Blankstein et al had shown that 80 % of EMBs obtained
from patients with RV-uptake were positive. As discussed previously, in that study
RV uptake was also associated with poor prognosis.111 The importance of RV-uptake
as prognostic factor was also shown by Wicks et al. When adjusted for LVEF, hazard
ratio in patients with RV-uptake was 5.84. Even higher hazard ratio of 25.0 was
found for RV LGE.129 Smedema et al found similar results in 84 patients with
pulmonary sarcoidosis suspected of having cardiac involvement. In CMR, 12
patients had LGE in the right ventricle and the finding was associated with a hazard
ratio of 8.7181
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3 AIMS OF THE STUDY
The overarching aim of the studies I-IV was to assess the role of FDG-PET in the
workup of patients with a clinical suspicion of cardiac sarcoidosis. More specifically
the aims were:
I to study the association of pathological PET findings, patient characteristics and
presenting symptoms to identify the patients that are most likely to benefit from the
PET-study.
II to study the association of PET findings and novel ECG-parameters
III to study the association of pathological cardiac and extracardiac PET findings
I and III to study the association of PET and biopsy findings
IV to study the prognostic value of visual and quantitative PET parameters
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4 MATERIALS AND METHODS
4.1 Study population
For this study, all cardiac PET studies performed in the Tampere University Hospital
from August 2012 to September 2015 were screened. We excluded studies in which
the clinical indication was not CS suspicion, if the patient’s clinical data could not be
obtained or PET study was performed to follow up previously diagnosed CS.
Imaging studies were also excluded if the dedicated imaging protocol described
below was not followed precisely. Altogether, 137 PET examinations were analyzed.
The whole population of 137 patients was analyzed in studies I, III and IV. In study
II, further four patients were excluded due to lack of ECG data.
In our hospital, PET is routinely performed in the diagnostic workup of possible
CS. The reason for a clinical suspicion of CS was one or more of the following:
unexplained atrio-ventricular (AV) block (n=61), ventricular (n=39) or
supraventricular (n=13) arrhythmia, unexplained dilated cardiomyopathy (n=27), or
unexplained low ejection fraction on echocardiography (n=46), other
echocardiographic findings suggestive of CS (n=53), or syncope (n=27). The
referring cardiologist considered the symptoms and clinical findings as inconclusive
after routine evaluation, including clinical examination, electrocardiography (ECG)
and echocardiography. Coronary angiography was performed in cases with a clinical
suspicion of coronary artery disease.
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Figure 2.  Flow chart on the patient selection process
4.2 PET-imaging
All patients underwent an integrated PET/CT (Discovery STE 16, GE Healthcare,
Milwaukee, WI, USA) examination. To minimize the physiological myocardial FDG
uptake, the patients were instructed not to consume any carbohydrates during the
day before the imaging and were fasting for 12 h before the FDG injection. The
patients kept a food diary during the diet. The patients were also instructed to avoid
heavy physical exercise to minimize FDG uptake in skeletal muscle. The patient’s
height and weight were measured before the administration of the
radiopharmaceutical, and their blood glucose level was tested to be <7 mmol/l. The
PET/CT images were acquired approximately 60 min after the intravenous injection
of FDG using the Medrad® Intego PET infusion system (Bayer Medical Care Inc.,
Indianola, PA, USA). The activity injected is currently based on the patient’s weight
(3-3.2 MBq/kg). However, the protocol was changed in 2013. Previously, patients
were given a fixed dose of 370 MBq. The mean injected activity in our study
population was 320 MBq (range 219-460 MBq). The imaging covered a volume of
two bed positions around the myocardium approximately from the level of shoulders
to the level of the gallbladder. The acquisition of the images was performed in the
220 cardiac PET-
studies
•3 studies to
diagnose
infected
prosthetic valve
or pacemaker
excluded
217 studies for
cardiac sarcoidosis
•80 studies for
follow up
purpose
excluded
137 studies for
further analyses
•4 studies
excluded from
study II due to
lack of ECG data
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three-dimensional (3D) mode with a 128*128 matrix, 70 cm field of view (FOV) and
5 min per bed position. The PET images were reconstructed using the 3D VUE
Point reconstruction algorithm (GE Healthcare) with 2 iterations and 28 subsets.
Gaussian 6.0 mm FWHM was used as the post-filter. The acquisition parameters of
the CT scanner were as follows: tube voltage, 120 kV; tube current automatic
exposure control range, 30 – 80 mA; noise index, 33 HU; rotation speed, 35 mm/rot;
and pitch, 1.75:1. The CT images were reconstructed to slice thicknesses of 2.50 mm,
with 1.25-mm intervals. The total examination time for the PET/CT was
approximately 15 min. CT was used for attenuation correction and the accurate
localization of uptake
4.3 Analysis of the PET-images
Cardiac uptake pattern in the left and right ventricular myocardium was classified
separately along lines recommended by the Japanese Society of Nuclear Cardiology
as ‘none’ (no activity exceeding normal blood pool activity), ‘global diffuse’ (uniform
activity over the entire myocardium), ‘focal’ (focally increased spot(s) of activity,
other regions inactive), ‘focal on diffuse’ (intense focal spot(s) of activity overlapping
global myocardial activity).  We also used an uptake pattern described as ‘diffuse
non-global’ (faint activity on at least two LV walls, but at least some areas of
myocardium with no activity over normal blood pool activity). This pattern is not
mentioned in the recommendations issued by Japanese Society of Nuclear
Cardiology but was considered to be a similar physiological phenomenon as diffuse
uptake. Different patterns are presented in figure 2. The uptake was considered to
be physiological when classified as none, global diffuse or diffuse non-global.
Myocardial uptake pattern was considered pathological if it was classified as focal or
focal on diffuse. Myocardial maximum standardized uptake value (SUVmax) was
measured and its location determined. Uptake in the lymph nodes outside heart was
considered pathological when exceeding that of the mediastinal blood pool. The
areas inspected for possible pathological extracardiac uptake included axillary,
subclavicular, mediastinal, hilar and epigastric lymph nodes. We also inspected lung
parenchyma, liver, spleen and bone marrow for possible pathological FDG uptake:
FDG-uptake in the spleen, liver, and lung parenchyma was considered pathological
if there were spots of metabolic activity exceeding the physiological uptake of the
surrounding parenchyma. Uptake was considered pathological in the bone marrow
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if there was focal uptake exceeding that of the liver. Image interpretation was
performed after patient anonymization and randomization by two experienced
nuclear medicine physicians (HT, 10 years of experience and KS, 15 years of
experience). The physicians interpreted the images separately, blinded to all clinical
data. In cases where the interpretation of LV uptake differed between the observers,
a consensus was reached and that was used in further analyses. After the initial
analysis, quantitative parameters were measured by HT using PETVCAR software
on GE Advantage workstation (GE Healthcare, Milwaukee, WI, USA). First, blood
pool mean standardized uptake value (SUVmean) was measured from the ascending
aorta. Descending aorta was used if there were active lymph nodes near to the
ascending aorta. A lower limit of SUV for abnormal cardiac uptake was defined as
blood pool SUVmean x 1.5. Using this value, pathological metabolic volume was
defined as volume where SUV-value exceeded the threshold. The volume did not
have to be continuous. Then SUVmean over the pathological metabolic volume was
measured and used to calculate total cardiac metabolic activity (tCMA) by
multiplying the metabolic volume by SUVmean.
Figure 3. Different types of cardiac uptake: No cardiac uptake (upper left), diffuse non global uptake
(upper middle), diffuse uptake (upper right), focal uptake (lower left) and focal on diffuse
uptake
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4.4 Analysis of the ECG recordings
One standard 12 lead ECG recorded with a 50 mm/s speed of each patient was
analyzed manually in a systematic manner. The analysis was performed blinded to
the clinical data by an experienced cardiologist member of the investigation group.
The ECG closest to the PET/CT study was used, but in the case it was a
pacemaker ECG, a previous ECG without pacing was chosen.
For the PQ interval and QRS duration, computer analysis measurements were
used.
Sokolow-Lyon criteria138 or Cornell voltage duration product [QRS-duration (ms)
× (RaVL in mm + SV3 in mm with 6 mm added for women) 2440].139,140 were
used to define left ventricular hypertrophy (LVH).
The criteria used for ST segment depression was  0.5 mm if the pattern was
horizontal or descending and 1 mm if ascending in 2 adjacent leads measured at
the J point+60 ms.141 T-wave inversion was defined as 1mmin2 adjacent leads,
except for leads aVR and V1.142
For fQRS in 2 adjacent leads, we used the definitions by Das et al. 64Septal
fragmentation was considered present if there was fQRS in 2 septal leads (V1-V3).
We considered fragmentation of >5 ECG leads as widespread fQRS.
For fascicular and BBB, standard criteria were used. Non-specific intraventricular
conduction defect (NSIVCD) was defined as a QRS duration 120 ms, not fulfilling
criteria for right (RBBB) or left BBB.
For II or III degree AV block, we used data from the patient history in addition
to the ECG analysis data.
In addition to the established ECG changes, we used a recently introduced ECG
parameter “Septal remodelling”,143 which was defined as one of the following
present in leads V1-V3:
1) Pathological Q waves in 2 parallel leads, and/or
2) Septal fQRS as defined above, and/or
3) Poor R-wave progression (R wave<3 mm) in leads V1-V3 accompanied by
fQRS, or disorderly distributed R-wave amplitudes, either RV2>RV3 or RV1>V2.144
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Figure 4. An example of ECG with both septal and inferolateral remodeling. Reproduced from II
There is QRS fragmentation present in V2-V3 and there is also poor R-wave
progression as RV2>RV3 fulfilling the criteria for septal remodeling. QRS is
fractioned also in leads II, III, aVT and aVF which fulfills the criteria for inferolateral
remodeling.  The criteria for widespread QRS fractioning is also fulfilled.
In addition, we introduced a novel ECG parameter “Inferolateral remodelling”,
which was defined as follows:
1) fQRS in 1 inferior (II, III, aVF) and lateral (V4-V6) lead, and/or
2) Q wave (as defined below) in 2 of the leads II, aVF, V4-V6, and/or
3) Low voltage (R-wave amplitude 3.5 mm) in II, III, aVF and V4-V6.
The possibility of a lead switch was considered by assessing the morphology of
the P and S waves in the precordial leads, and no suspicious cases were observed.
Any Q wave 40 ms in duration, or 3 mm deep, or qR-ratio  0.25, in 2 parallel
leads except lead aVR was considered pathological.145
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4.5 Collection of clinical data
Clinical data were retrospectively collected from the electronic medical record
system of Tampere University Hospital, which contains information from 2008
onward. The initial data collection was performed between January and May 2016.
At that time, we collected demographic information, echocardiography findings,
MRI-findings, relevant diagnoses, symptoms and endomyocardial biopsy (EMB)
findings, deaths, healthcare visits and hospitalizations for ventricular
tachyarrhythmia. Systolic function evaluated by echocardiography was categorized
as normal (> 50 %), decreased (35-50 %) or (poor < 35 %). Echocardiography
findings were collected from studies performed nearest to PET-study and the last
echocardiography study of the follow-up period. Diagnosis of CS by cardiologists
was based on EMB or a combination of other biopsy verification of sarcoidosis and
clinical and/or imaging findings indicating cardiac involvement. Electronic health
record data for follow-up was available from the Tampere University Hospital.
For follow-up purposes, a new round of data collection was performed in
November 2017. At that time, we collected data for cardiac events after the initial
PET-study. Cardiac events of interest were reduction in LVEF, hospitalization due
to cardiac arrhythmia, and death. Change in LVEF was determined by comparing
the findings between echocardiography studies performed nearest to the PET study
and the last study of the follow-up period. Decrease in LVEF was defined as a
negative change in LVEF category defined above. We used hospital admission as a
definition of severe ventricular arrhythmia as the number of other detected
ventricular arrhythmias was highly dependent on whether or not the patient had a
pacemaker or implanted cardioverter-defibrillator (ICD).
4.6 Statistical methods
IBM SPSS version 22.0 (Armonk, NY,USA) and R Software version 3.2.2 were used
for data analysis in original articles I-IV.
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In the article I on the association of patient characteristics, symptoms and clinical
findings to PET imaging findings, chi-square test was used to compare dichotomous
variables between groups. For continuous variables, T-.test was used. In this study,
inter-observer agreement in PET-interpretation was tested using kappa statistics.
In article II on the association of ECG parameters and PET-findings, Chi-square
and T-tests were used to compare dichotomous and continuous variable between
patients with and without pathological cardiac FDG-uptake. A logistic linear
regression analysis was used to test the independent relations between different ECG
parameters and pathological myocardial FDG-uptake in PET. The regression model
was adjusted for age, sex, body mass index (BMI), cardiovascular disease and cardiac
medication.
In article III on the association of pathological extracardiac and myocardial FDG-
uptake, results were compared using chi-square for dichotomous and T-test for
continuous variables. A logistic linear regression was used to assess the independent
associations of age, sex, pathological left- and right ventricular FDG-uptake and
pathological extracardiac FDG-uptake to biopsy findings confirming sarcoidosis.
In article IV on the ability of PET-findings to predict adverse cardiovascular
events, T-test was used to compare quantitative PET-parameters between patients
with and without cardiovascular events during follow up. Chi-square test was used
to compare dichotomous variables between these groups. For survival analysis, log-
rank was used to test the ability of pathological LV-, RV- and extracardiac FDG-
uptake and LVEF to independently predict cardiovascular events during follow up.
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5 RESULTS
5.1 The inter-observer agreement in interpreting the PET-
images
The inter-observer agreement for pathological left ventricular FDG-uptake between
two interpreters was found to be good as the kappa-value was 0.762.
5.2 Myocardial PET-findings
There were 104 patients with no pathological myocardial FDG-uptake: 85 had no
uptake exceeding blood-pool activity, three had diffuse uptake and 16 patients had
diffuse non-global uptake pattern. Thirty-three patients had pathological myocardial
FDG-uptake in the left ventricle: Of those, 28 had focal uptake and five had focal-
on-diffuse pattern. Different uptake patterns are presented in figure 5. Cardiac
SUVmax was higher in patients with pathological uptake pattern compared to those
with no pathological FDG-uptake 8.5 (SD 4.1) and 3.4 (SD 1.3), respectively (p-
value <0.001) Qualitative and quantitative PET-findings for the whole population
are presented in table 6.
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Figure 5. Uptake pattern frequencies in left and right ventricle
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Frequency of uptake patterns in the left venrticle
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Diffuse non-global uptake
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Focal uptake
Focal on diffuse uptake
90,5%
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Frequency of uptake patterns in the right
ventricle
No uptake
Diffuse non-global uptake
Diffuse global uptake
Focal uptake
Focal on diffuse uptake
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Table 6.  Qualitative (a) and quantitative (b) PET-findings for the whole population (n=137)
a)
Qualitative PET-findings n %
LV-uptake 33 24
LV- and RV-uptake 12 9
extracardiac uptake 29 21
b)
Quantitative PET-findings mean SD
SUVmax 4,6 3,1
Pathological metabolic volume (cm3) 50 104
SUVmean 2,6 1,3
tCMA (MBq) 193 454
Of the 33 patients with pathological FDG-uptake in left ventricular myocardium,
twelve had pathological uptake in the right ventricular free wall also. There were no
patients with pathological uptake in the right ventricular wall without left ventricular
uptake. Patients with uptake in both ventricles had higher cardiac SUVmax than
patients with uptake in the LV only: 11.8 (3,8) and 6.6 (2.8), respectfully (p-value
0.001). Quantitative parameter total cardiac metabolic activity was highest in patients
with uptake in both ventricles: 914 (SD.706) compared to 404 (567) in those with
LV uptake only and 123 (SD 356) MBq in those with no pathological cardiac uptake.
(p-value <0.030 between both ventricles and LV-only and <0.001 between LV-only
and no pathological uptake). (Unpublished data). (Figure 6)
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Figure 6. Quantitative PET-parameters in patients with no pathological uptake, uptake in the left
ventricle only and in patients with uptake in both ventricles
LV = left ventricle; RV = right ventricle. P-values represented between those with
no pathological uptake and LV-uptake only and between those with LV-uptake only
and uptake in both LV and RV.
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5.3 Pathological cardiac PET-findings in relation to patient
characteristics
Patient demographics in those with and without pathological LV- and RV-uptake
are presented in tables 1 and 2. There were 80 male and 57 female patients in the
study population. Thirteen (16 %) male and 20 (35 %) female patients had abnormal
LV uptake. The frequency of pathological myocardial FDG-uptake was significantly
higher in women. Of the 12 patients with pathological RV-uptake, 10 were female
(p-value 0.002).
In our population, 56 patients had a history of 2nd or 3rd degree AV-block. Of
these patients 41 % had pathological FDG-uptake compared to 12 % of those
without advanced AV-block (p-value <0.001). The frequency of pathological FDG-
uptake was 56 % in female patients with advanced AV-block (n=27). In male patients
with no or mild AV-conduction abnormality (n=46), the frequency of pathological
myocardial FDG-uptake was only 6 %.
Seventy-five patients had a history of ventricular tachyarrhythmia. Of those, 23
(31 %) had pathological left ventricular FDG-uptake and 11 (15 %) had pathological
right ventricular FDG-uptake. Of the 12 patients with pathological RV-uptake, 92
% had a history of VT.  The association was statistically significant between history
of VT and RV-uptake (p-value 0.006) but did not reach significance for LV-uptake
(p-value 0.053). Patient characteristics and reasons for referral in patients with and
without pathological LV and RV uptake are presented in tables 7 and 8, respectively.
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Table 7.  Baseline variables in patients with pathological or normal left ventricle FDG-PET-
finding. (reproduction from I)
Variable
Abnormal
LV-uptake
(n =33)
Normal LV-
uptake
(n=104)
p-value
Gender, female/male 20/13
(61/39%)
37/67
(36/64%)
0.002*
Age, years 45.8 ±12.1 43.7 ±13.2 0.401
Body mass index 26.2 ±3.9 28.3 ±5.9 0.053
History of:
     II or III degree AV-
block 23 (70%)
33 (32%) <0.001
     Ventricular tachycardia 23 (70%) 52 (50%) 0.053
     Atrial fibrillation 16 (49%) 37 (36%) 0.185
     Heart failure 14 (42%) 53 (51%) 0.393
     Pulmonary sarcoidosis 10 (30%) 17 (16%) 0.208
     Any heart disease 22 (67%) 64 (62%) 0.595
Reasons for referral:
     AV-block 25 (76%) 35 (34%) <0.001*
     Supraventricular
arrhythmia
3 (9%) 10 (10%) 0.541
     Ventricular arrhythmia 5 (15%) 34 (33%) 0.052
     Dilated cardiomyopathy 6 (18%) 22 (21%) 0.712
     Abnormal echo findings 14 (43%) 39 (38%) 0.613
     Syncope 6 (18%) 22 (21%) 0.712
CS-positive EMB§ 6 (18%) 1 (1%) 0.190
Figures are n (%) for dichotomous and mean (+/- SD) for continuous variables.
Abbreviations: CS=cardiac sarcoidosis; EMB=endomyocardial biopsy; FDG-PET=
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¹΄Fluorodeoxyglucose positron emission tomography; LV= left ventricle; AV=atrio-
ventricular. § EMB was obtained from 21 patients.
Table 8. Baseline variables in patients with or without pathological right ventricular FDG-
PET-finding. (reproduction from I)
Variable
Abnormal
RV-uptake
(n =12)
Normal RV-
uptake
(n=125)
p
Gender, female/male 10/2 49/76 0.004*
Age, years 44.7 ±8.2 44.1 ±13.3 0.878
Body mass index 28.0 ±5.7 25.8 ±4.1 0.188
History of:
     Ventricular tachycardia 11 (92%) 64 (52%) 0.006*
     Atrial fibrillation 8 (67%) 45 (36%) 0.040*
     Heart failure 5 (42%) 62 (50%) 0.413
     Pulmonary sarcoidosis 4 (33%) 23 (18%) 0.249
     Any heart disease 10 (83%) 76 (61%) 0.106
Reasons for referral:
     AV-block 10 (83%) 50 (40%) 0.004*
     Supraventricular             1 (8%) 12 (10%) 0.682
     Ventricular arrhythmia 4 (33%) 35 (28%) 0.461
     Dilated cardiomyopathy 1 (8%) 27 (22%) 0.250
     Abnormal echo findings 5 (43%) 48 (38%) 0.527
     Syncope 4 (33%) 24 (19%) 0.209
CS-positive EMB§ 4 (33%) 3 (2%) 0.537
Figures are n (%) for dichotomous and mean (+/- SD) for continuous variables.
Abbreviations: CS=cardiac sarcoidosis; EMB=endomyocardial biopsy; FDG-PET=
¹΄Fluorodeoxyglucose positron emission tomography; RV= right ventricle;
AV=atrio-ventricular. § EMB was obtained from 21 patients
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5.4 Pathological extracardiac FDG-uptake
Of the 137 patients, 29 had pathological FDG-foci outside myocardium.
Extracardiac uptake foci were most often found in mediastinal and/or hilar lymph
nodes (n= 24) and lung parenchyma (n=14). Metabolically active foci were also
found in spleen (n=5), axillary (n=5), subclavicular (n=5) and epigastric (n=6) lymph
nodes.
Table 9.  Frequency of extracardiac uptake at different sites
Extracardiac uptake site n %
any extracardiac uptake 29 21
    Lung 14 10
    Spleen 5 4
    Mediastinal lymph nodes 23 17
    Hilar lymph nodes 24 18
    axillary lymph nodes 5 4
    Subclavicular lymph nodes 5 4
    Epigastric lymph nodes 6 4
    Bone marrow 1 1
The frequency of extracardiac uptake was higher in female patients (33 % in female
and 13 % in male patients, p-value 0.006). The patients with pathological extracardiac
uptake more often had history of ventricular tachyarrhythmias than patients with no
pathological extracardiac uptake (p-value 0.035). They also had history of cardiac
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insufficiency less often than those with no abnormal extracardiac uptake (p-value
0.010). (Table 10)
There was a significant association of pathological cardiac and extracardiac
uptake: Of the 33 patients with pathological cardiac uptake 16 (48 %) had
pathological extracardiac FDG-uptake compared to 13 (13 %) of the 104 patients
with no pathological cardiac uptake (p-value <0.001). The association was even more
pronounced for those with pathological right ventricular uptake as 10/12 (83 %)
compared to 19/125 (15 %) in those with no pathological RV-uptake had
extracardiac uptake (p-value <0.001). Patient characteristics and PET-findings in
patients with and without extracardiac uptake are presented in table 10.
The analysis of associations between different extracardiac uptake sites and
pathological cardiac uptake revealed that there was association only between
mediastinal and hilar lymph node uptake and pathological myocardial uptake
(p<0.001 for both). There was no significant difference in the frequency of
extracardiac fdg-uptake sites other than mediastinal/hilar between those with and
without pathological cardiac uptake (p-values for different sites ranging from 0.085-
0.652).
Fourteen patients had pathological cardiac uptake but had no prior known
sarcoidosis or extracardiac uptake. Two of them had CS verified by EMB.
Figure 7. Patients with LV, RV and extracardiac uptake: Each circle represent the
number of patients with uptake in left ventricle (black), right ventricle (green) and outside
heart (red). Overlap of specific circles represents the combination of uptakes, for example,
there is 10 patients with uptake in LV, RV and outside heart.
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Table 10. Baseline variables and FDG-PET-findings in patient with and without pathological
extracardiac FDG-uptake (representation from III)
Variable Pathological
extracardiac
FDG-uptake
(n=29)
No
pathological
extracardiac
FDG-uptake
(n=108)
p-value
Female gender 19 (66 %) 40 (37 %) 0.006*
BMI 27.3 (4.2) 28.0 (5.9) 0.525
Age, years 44.1 (12.3) 44.2 (13.2) 0.97
History of:
   Ventricular tachycardia 21 (72 %) 54 (50 %) 0.035*
   II or III degree AV-block 14 (48 %) 42 (39 %) 0.241
   Cardiac insufficiency 8 (28 %) 59 (55 %) 0.01*
LV-uptake 16 (55 %) 13 (12 %) <0.001*
RV-uptake 10 (34 %) 2 (1,9 %) <0.001*
Extracardiac biopsy positive
for sarcoidosis
11 (38 %) 4 (4 %) <0.001*
EMB or extracardiac biopsy
positive for sarcoidosis
15 (52 %) 7 (7 %) <0.001*
Figures are n (%) for dichotomous and mean (+/- SD) for continuous variables.
Abbreviations: BMI=Body mass index; EMB=endomyocardial biopsy; FDG-PET=
¹΄Fluorodeoxyglucose positron emission tomography; AV=atrio-ventricular; RV=
right ventricle; LV left ventricle
60
5.5 Association of ECG- and PET-finding
The association of different ECG parameters and pathological cardiac PET-findings
were analyzed in 133 patients who had ECG data available. Thirty-two of these
patients had pathological myocardial FDG-uptake.
Pathological LV-uptake was associated with septal remodeling, inferolateral
remodeling, widespread QRS fractioning and ventricular conduction abnormalities
(defined as any bundle branch block). The association of bundle branch block and
pathological LV-uptake was explained by left anterior fascicular block that was the
only ventricular conduction defect that was significantly more frequent in patients
with pathological LV-uptake. The frequencies of different ECG parameters with
regard to cardiac PET finding are presented in table 11.
There were no significant associations between pathological myocardial FDG-
uptake and PQ-interval length or the presence of advanced (II or III degree) AV-
block. Neither was there significant difference between those with and without
pathological cardiac uptake with respect to Q-waves, LVH, T-inversion, ST-segment
depression, poor R-wave progression or fractioned QRS in at least 2 adjacent leads.
The association of pathological cardiac FDG-uptake and septal remodeling,
inferolateral remodeling and widespread fQRS remained significant when adjusted
for sex, age, BMI, cardiac medication, presence of underlying cardiac disease and
history of II or III degree AV-block (p-value <0.05 for all).
The number of patients diagnosed by EMB was low in our population. Of the
seven patients with EMB findings indicating CS, five had a finding of septal
remodeling in their ECG.
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Table 11. ECG parameters in patients with or without pathological cardiac FDG uptake. Modified
from II
ECG parameter Physiological
cardiac uptake
(n=101)
Pathological
cardiac uptake
(n=32)
p-
value
PQ interval (ms) 191.7 ± 56.0 222.3 ± 79.7 0.069
Poor R wave progression (%) 20 29 0.493
Left ventricular hypertrophy (%) 25 14 0.387
ST segment depression (%) 22 21 0.959
T wave inversion (%) 37 43 0.669
QRS fragmentation (%) 60 69 0.395
Septal remodelling (%) 15 44 0.001*
Inferolateral remodelling (%) 9 28 0.006*
RBBB (%) 14 22 0.279
LBBB (%) 7 9 0.648
LAFB (%) 10 28 0.010*
Any intra-ventricular conduction
defect (%)
35 56 0.030*
AV block (II or III degree) (%) 9 13 0.532
Widespread (N5 leads) fQRS (%) 22 50 0.002*
Values are means ± SD in continuous variables and % in dichotomous variables.
RBBB = right ventricular bundle branch block, LBBB = left bundle branch block,
LAFB = left anterior fascicular block; LPFB = left posterior fascicular block; AV=
atrioventricular, fQRS = QRS fragmentation. *p-value < 0.05
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5.6 Biopsy findings confirming sarcoidosis and their association
with PET results
In our population, endomyocardial biopsy was obtained from 21 patients. The
histology was suggestive of cardiac sarcoidosis in seven patients. Six of the seven
patients had pathological LV uptake and four had uptake in both ventricles.
However, due to the low number of biopsies the association between cardiac FDG-
uptake and positive EMB did not reach significance (p-value 0.190).
A biopsy from an extracardiac site was obtained in 25 patients and in 15 it was
indicative of sarcoidosis. There was a significant association of pathological
extracardiac FDG-uptake and sarcoidosis-positive biopsy finding (p-value<0.001).
In a logistic regression model including LV uptake, RV uptake and extracardiac
uptake, only the last was associated to positive biopsy finding (extracardiac or
endomyocardial).
Figure 8. Patients divided into groups according to PET-findings and the number of tissue biopsies
(EMB or other) positive for sarcoidosis
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5.7 The ability of FDG-PET to predict adverse cardiac events
During the average follow-up of 55 months, eleven patients had one or more adverse
cardiovascular (CV) event. Seven patients were hospitalized for ventricular
tachyarrhythmia, LVEF decreased in five patients and three died. No significant
difference in any baseline characteristics, including LVEF, were observed between
patients who had CV events and those who had no events.
Out of 33 patients with pathological LV-uptake, five had an adverse cardiac event
during follow up. All those also had uptake in the right ventricle. RV uptake but not
LV-uptake was significantly associated to CV events (p-values <0.001 and 0.091,
respectively). Baseline characteristics and PET findings in patients with and without
events are presented in table 12.
Quantitative metabolic PET parameters, specifically cardiac SUVmax and total
cardiac metabolic activity (tCMA) were higher in patients with events compared to
those with no events: 7.1 vs 4.4 and 530 MBq vs 163 MBq, respectively (p<0.001
for both).
A cut-off value of >900 MBq was used to define high tCMA. There were 8
patients with tCMA exceeding that and three (38 %) of them had an event during
follow up compared to 6 % of those with tCMA<900 MBq. All three patients with
events and high tCMA also had pathological uptake in the RV.
In a multivariate survival analysis, high tCMA and RV uptake were significant
predictors for events (p-values 0.032 and <0.001, respectively). Decreased baseline
LVEF, pathological LV-uptake or extracardiac FDG-uptake did not significantly
predict CV events during follow up (p= 0.094, 0.217 and 0.489, respectively).
Cardiac sarcoidosis was diagnosed in 18 patients according to diagnostic criteria.
There was no significant difference in the frequency of CV events between patients
who were diagnosed with CS and those who were not (p-value 0.148).
Survival curves for patients with and without pathological RV uptake are
presented in figure 9 and survival curves for patients with low and high tCMA are
presented in figure 10
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Table 12. Baseline characteristics, PET-findings and treatment during follow up in patients with
and without events during follow up
Patients with
events n=11
Patients with no
events n=126
p-value
Baseline characteristics
Female sex 45% (5) 43% (54) 0.556
Age, y (SD) 37 (8) 45 (13) 0.062
Follow-up, mo (SD) 50 (8) 44 (11) 0.059
Reduced LVEF at baseline 73% (8) 54% (68) 0.190
PET findings
Pathological LV-uptake 46% (5) 22% (28) 0.091
Pathological RV-uptake  46% (5) 6% (7) <0.001*
tCMA>900 MBq 27% (3) 4% (5) 0.018*
Extracardiac uptake 36% (4) 20% (25) 0.180
SUVmax 7.1 (5.6) 4.4 (2.8) <0.001*
Metabolic volume (cm3) 105 (167) 44 (96) 0.050
tCMA (MBq) 530 (886) 163 (388) <0.001*
Values are % (n) for dichotomous and mean (SD) for continuous variables.
LVEF=Left Ventricular Ejection Fraction; LV=Left Ventricle; RV=Right Ventricle
SUV=standardized uptake value; Metabolic volume =Volume of myocardium with
SUV>1.5 x aortic reference SUV; tCMA=total cardiac metabolic activity calculated
as SUVmean x Metabolic volume *p-value < 0.05
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Figure 9.  Survival free of cardiac events in patients with no right ventricular uptake and in those
with pathological right ventricular uptake. Between groups the p-value is 0.001.
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Figure 10.  Survival free of cardiac events in patients with tCMA below or above 900 MBq. Between
groups the p-value is 0.032
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6 DISCUSSION
6.1 Methodological considerations
This is a retrospective study on a clinical cohort of patients with suspected cardiac
sarcoidosis referred to cardiac FDG-PET study. Our selection criteria were relatively
loose: patients were included if the referring cardiologist had suspicion of CS based
on symptoms and findings after other possible causes for the symptoms were ruled
out by clinical examination, ECG and echocardiography and coronary angiography
when considered necessary. For this reason, our population is representative of a
true clinical situation faced by physicians interpreting the images and clinicians
considering the significance of imaging results.
The loose inclusion criteria also lead to the fact that a majority of the subjects do
not have CS, but some other yet unrecognized cardiac disease. This resulted in the
relatively low frequency of pathological cardiac PET findings compared to other
studies (discussed later). The frequency of CS diagnosed according to the criteria was
also low and CS verified by EMB even lower.
In the nuclear medicine department of Tampere University Hospital, it is not
common to perform myocardial perfusion imaging (MPI) study in combination with
FDG-PET in suspicion of myocardial inflammation. This is somewhat contrary to
international practice.101 MPI data might have increased the sensitivity as non-active
late phase sarcoidosis might have been detected. However, of the seven patients who
were diagnosed to have CS by EMB only one was PET-negative. Anyhow, including
MPI must be considered in possible prospective trials in the future.
Our study population was 137 patients, which is in scale with populations in other
larger studies on CS. However, the relatively low number of positive cardiac PET-
findings hindered the use of robust multivariate logistic regression analysis to
determine the independent role of different pre-test variables in predicting positive
PET-results in studies I and IIII. The same problem was encountered in IV when
trying to determine the independent prognostic role of PET-related and other
variables.
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We encountered the common problem concerning most studies on CS, namely
the lack of diagnostic gold standard. Verification by EMB is specific but its low
sensitivity and risk of complications especially in left ventricular biopsies limits its
usefulness. For this reason, we did not make conclusions on the accuracy of FDG-
PET in diagnosing CS. To draw a reliable conclusion on accuracy figures would
demand a prospective study with rigorous diagnostic scheme optimally including
multiple endomyocardial biopsies when necessary.
The clinical presentation and prognosis of CS is known to vary between different
ethnic populations. Our study population consists of patients of Caucasian origin
and thus our findings should be interpreted with caution in relation to other ethnic
populations.
The number of adverse events in IV remained low because we only included
ventricular tachycardias that had led to hospital admission. Including all VTs was
considered but was later discarded as the initial analyses indicated that the amount
of registered VTs was highly dependent on whether or not the subject had a
pacemaker or ICD. This could have led to falsely high number of events in patients
with positive PET findings as ICD was often implanted in such patients as the
cardiologists considered them to be in risk of serious rhythm disturbances (even as
PET is not included in risk stratification in the 2014 HRS consensus statement).47
6.2 The results in reflection to existing literature
6.2.1 Success in reducing physiological myocardial uptake
Physiological myocardial uptake was observed in 18.5 % of patients: 2.2 % had global
diffuse uptake, 12.7 had diffuse non-global uptake and 3.6 had diffuse uptake under
focal pathological spots. This is in line with the figures of up to 20 % in of studies
applying the same patient preparation procedures (non-carbohydrate diet combined
to fast).94 On this basis, our patient preparation protocol and resulting image quality
is up to international standards.
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6.2.2 Inter-observer agreement
The inter-observer agreement on whether the cardiac uptake pattern was
pathological or not was found to be good between two experienced nuclear medicine
physicians (kappa value 0.76). This is somewhat better compared to 0.72 found by
Gromsen et al.146 The difference might be explained by the fact that in their study,
there were four interpreters and that in their population complete suppression of
myocardial FDG-uptake was achieved in only 11 % of patients compared to our 62
%. Assumedly, the low proportion of patients with complete suppression
complicates the interpretation of images.
6.2.3 Frequency of positive PET findings
In our population, 24 % of patients had pathological myocardial uptake. In previous
studies on FDG-PET in suspected CS the proportions of patients with pathological
myocardial uptake has varied widely. In the 17 studies included in a recent meta-
analysis, the average proportion of positive PET findings was 31 %. The range was
wide, from 6 % up to over 60 % depending on the patient population. Some recent
studies are listed in table 13. Considering the relatively loose inclusion criteria in our
population, the results are well in line with other existing literature.
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Table 13. Proportions of positive myocardial PET-findings in other studies on FDG-PET in
suspected CS.
Study Population imaging
methods
Positive findings
Ohira
2008122
21 patients with
pulmonary
sarcoidosis
CMR +
PET
FDG uptake 71 % LGE
38 %
Manabe
2013124
59 patients with
biopsy-proven
extracardiac
sarcoidosis
PET FDG uptake 59 %
Blankstein
2013111
118 patients
evaluated for
suspected or
known CS
PET+
perfusion
imaging
FDG uptake or perfusion
defect 60 %
Soussan
2013147
58 sarcoidosis
patients with
suspected CS
PET FDG uptake 34 %
Ahmadian
2014127
38 suspected CS PET FDG uptake 61 %
Yokoyama
2015148
92 suspected CS PET FDG uptake 60 %
Momose
2015149
52 suspected CS PET FDG uptake 65 %
Wicks
2018129
51 suspected CS PET +
MR
FDG uptake 55 % LGE
63 %
Schidt
2018150
231 suspected CS PET +
PERF
Pathological pattern 20 %
Sgard
2019151
80 with
sarcoidosis and
suspected CS
PET+
MRI
FDG uptake 14 % LGE
43%
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Pathological right ventricular uptake was found in 12 of our 137 patients. There are
few studies mentioning right ventricular uptake. In the 2008 study on 21 patients
with pulmonary sarcoidosis and suspicion of CS by Ohira, 1 patient (5 %) had RV-
uptake.122 Manabe et al studied 59 patients with biopsy-proven sarcoidosis and found
RV-uptake in 13 patients (22 %).124 In the much-cited study by Blankstein et al on
prognostic role of FDG-PET, there were 11 out of 118 patients (9 %) with RV-
uptake.111 Wicks found RV-uptake in 4/51 (8 %) patients with suspected CS and
Omote found a high proportion of 12/28 (43 %) in patients with diagnosed CS.129,137
Our results on the frequency of RV-uptake fall in line with studies on FDG-PET in
suspected (but not diagnosed) CS.
There were no patients with RV uptake without LV uptake. This situation seems
to be very rare as only one mention of such uptake pattern on one patient can be
found in the literature.124
6.2.4 Patient demographics, history and PET findings
We found that pathological myocardial FDG-uptake was more frequent in females
and in those with a history of II or III degree AV-block. In addition, there was an
association of RV uptake and history of ventricular tachyarrhythmias.
The association of AV-block and inflammatory myocardial disease is relatively
well established. In our population, there were 56 patients with a history of AV block
and 12 (21 %) of them showed pathological myocardial FDG-uptake in PET.
Previously, Kandolin et al found CS in 22/76 patients with advanced AV-block.33
Nery et al found similar results in 33 patients with advanced AV-block with 11 (34
%) patients subsequently diagnosed with CS.32 The association of pathological FDG-
PET results and AV-block was also observed on another study by Nery et al on
patients with unexplained VT tendency.4 Furthermore, There is evidence of
association between uptake in basal septum and AV-block.124
Our results on association of AV-conduction block and pathological cardiac PET
findings may seem somewhat confusing, as there was association between history of
AV block and PET findings and no association of AV-block in the ECG nearest to
PET and pathological myocardial FDG-uptake. This may be explained by the
tendency of AV conduction block in CS to be variable. This is acknowledged in HRS
consensus statement on treatment of conduction disturbances as pacemaker
implantation is recommended even if advanced AV-block has receded.47 Thus, a
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notion of advanced AV-block in patient history can be considered to be more
sensitive sign than AV-block in a single ECG recording.
Right ventricular uptake was more frequent in patients with a history of
ventricular tachycardias. Nery et al have shown the association of VTs and
myocardial FDG-uptake in a small population.4 Tung et al have also shown the
association as 49 % of patients with cardiomyopathy and VTs had pathological
cardiac FDG-uptake on PET.125
The studies above do not mention the site of pathological cardiac FDG uptake.
There is scarce evidence for the association of RV uptake and ventricular
tachycardias. However, it has been shown that patients with RV scarring shown by
LGE in CMR have a higher risk of VT among other cardiac events.81 The association
of RV involvement in CS and ventricular tachycardias have also been shown in
electrophysiological studies.58,152
The higher frequency of pathological FDG-uptake in female patients has not
been reported previously. Our population had more male than female patients,
although a majority of diagnosed Finnish CS patients are female.3 This may indicate
that female patients who were referred to PET study had signs and/or symptoms
more specific to CS. Indeed, male patients were referred to PET more often than
females for unexplained cardiac insufficiency, which has a multitude of underlying
causes. In this manner, the higher frequency of pathological PET findings can be
explained by patient selection, but it also gives valuable information for clinicians as
it indicates that the suspicion of CS is more often accurate in female patients.
As another proof of unspecific nature of cardiac insufficiency as a symptom of
CS is our finding that the frequency of pathological extracardiac FDG-uptake was
significantly lower in patients with cardiac insufficiency. In patients suspected for
CS, extracardiac foci are considered to represent active systemic sarcoidosis. We
found that the presence of extracardiac uptake was the only independent predictor
of a biopsy verification of sarcoidosis.
6.2.5 Association of ECG and PET findings
Association was observed between pathological PET findings and newly developed
ECG parameters septal remodeling and inferolateral remodeling. They combine
different signs of myocardial damage, namely Q-waves, poor R –wave progression
and QRS fragmentation (fQRS).
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Previously, it has been shown that standard ECG has low accuracy in detecting
CS.61 Lately, new parameters based on QRS fragmentation have been developed for
ECG analysis and these have been shown to associate with different structural heart
diseases, including cardiac sarcoidosis.63-66
The existing literature on association of PET- and ECG findings in suspected CS
is scarce. Manabe et al found an association between ECG abnormality, defined as
RBBB, AV-block, frequent ventricular extrasystolia, VT or left axis deviation, and
number of pathological LV-segments in FDG-PET. They found AV-block to be the
only ECG parameter significantly correlating with myocardial inflammation.124
We found no association between pathological myocardial FDG-uptake and QRS
fragmentation, a result seemingly in contradiction with the association of CS and
fQRS mentioned previously. However, QRS fragmentation is considered to
represent myocardial scarring so it could be considered natural that there was no
association of active myocardial lesion shown by FDG-PET and fQRS. However,
the association was positive for widespread fQRS (>5 leads). One could speculate
that in these cases the granulomatous inflammation in the myocardium is extensive
and lesions in different stages coexist.
RBBB has been shown to associate with pathological myocardial FDG uptake,
although less strongly than AV-block.123 We also found an association between
ventricular conduction defects and pathological LV-uptake but that was dependent
on LAHB. RBBB was not significantly associated with myocardial uptake. This could
be explained by the hypothesis that RBBB is a sign of more advanced disease. It is
possible that with heightened awareness of CS our patients were referred for imaging
at an earlier phase.
The novel ECG parameters of septal and inferolateral remodeling were
significantly associated with pathological FDG uptake, even after adjusting with sex,
BMI, age, cardiac medication, coexisting cardiac disease and history of advanced AV-
block. Our results are preliminary but the ability of septal remodeling to predict
positive PET-finding better than AV-block in the same ECG (odds ratio 5.9 and 4.5,
respectively) may prove clinically significant if it can be verified in future studies.
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6.2.6 Extracardiac uptake foci are important in the diagnostic process
We found an association between pathological FDG uptake in right ventricular
myocardium and mediastinal/hilar lymph nodes. Furthermore, biopsy verification
of sarcoidosis was more common in patients with inflammatory extracardiac foci.
Kandolin et al found FDG-uptake in mediastinal lymph nodes in majority of
Finnish patients diagnosed with CS. This also held true for patients without
previously known systemic sarcoidosis.3 Although Blankstein et al found no
association between cardiac and extracardiac FDG-uptake, this has been observed
in many other studies on FDG-PET in suspected CS.109,111,153 Lately, Schildt et al
have shown similar high frequency of extracardiac foci in patients with CS. They also
observed a more pronounced heterogeneity of myocardial FDG-uptake in patients
who had extracardiac foci.150 Heterogeneity of FDG-uptake could be interpreted as
a sign of more widespread inflammatory process in a similar manner to RV-uptake.
Diagnosis of CS warrants biopsy verification of sarcoid inflammation either
directly from myocardium (EMB) or from an extracardiac site if there is clinical and
imaging data indicating cardiac involvement. Obtaining an EMB carries a risk and it
has poor sensitivity. For this reason, a biopsy from an extracardiac site is often more
viable option. Whole body PET/CT has an important role in demonstrating possible
sites for tissue sample collection. This explains our finding that a biopsy indicative
of sarcoidosis was obtained more often in patients who had pathological uptake foci
outside heart. In the study population of Kandolin et al comprising of all diagnosed
cases of CS in Finland, the diagnosis was based on extracardiac biopsy on 50 % of
patients.3 In our population, the situation is more complicated as only a minority of
patients have CS. There were seven patients with extracardiac biopsy indicating
sarcoidosis but no cardiac FDG-uptake. These patients have no active myocardial
inflammation but late-phase inactive CS can’t be excluded by PET only. In these
cases, perfusion imaging data would have been valuable to diagnose possible inactive
disease.
Our results show the importance of extracardiac PET-findings in the diagnostic
process of CS in patients who have signs of myocardial disease in PET or other
diagnostic modalities.
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6.2.7 PET as a predictor of adverse cardiovascular events
One of the central findings of the study has been the important role of pathological
FDG-uptake in the right ventricle. In our population, RV uptake predicted adverse
cardiac events defined as hospital admission due to ventricular tachyarrhythmia,
degradation of LVEF, or death. As a slight surprise, the association of pathological
cardiac uptake and events was not significant. However, there was a clear association
between RV uptake and events. Along with tCMA it was the only independent
predictor of events in survival analysis. RV uptake predicted events similarly in
patients with diagnosed CS and in those without a firm diagnosis of CS.
The role of RV involvement was described by Blankstein et al, who observed a
five-fold risk of cardiac events was associated to RV uptake.111 Wicks et al found
similar figures for FDG-uptake in the RV with OR of 5.84 and even higher risk (OR
25.0) associated with LGE in the right ventricle.129 In addition, the association of
right ventricular LGE and poor prognosis was observed by Smedema et al.81
We also measured cardiac SUVmax and calculated total cardiac metabolic activity
(tCMA) that is a product of metabolic volume and mean SUV (calculation of tCMA
has been described in more detail previously). SUVmax can be understood as
measure of intensity of inflammatory activity. In theory, there could be one small
spot with very intense accumulation of inflammatory cells producing high SUVmax.
In such case, tCMA would not be very high as metabolic volume would be small.,
However, this is not the case in the reality as PET has suboptimal spatial sensitivity
and a very small focus is observed less intense than it really is due to partial volume
effect. For this reason, the differences of tCMA and SUVmax are attenuated.
In our population, high tCMA was associated to CV events. Similar results were
reported previously by Ahmadian et al, and tCMA has been shown to be useful in
follow up as its decline has been associated with better prognosis.127,132 SUVmax was
also significantly higher in patients with CV events during follow up. Anyhow, its
independent predictive role is questionable as SUVmax was higher with patients with
RV-uptake.
The role of RV uptake as a predictor of adverse event is logical. As all patients
with uptake in the right ventricle also had left ventricular uptake, they had a more
widespread myocardial inflammation. This in turn can cause extensive damage with
perilous consequences. The situation could be compared to coronary artery disease:
blockade of a distal branch of a coronary artery may produce a small infarct but is
normally not lethal. However, when there is a proximal blockade of a coronary artery
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the infarcted area will be large and is likely to cause cardiac insufficiency and severe
arrhythmias. Similarly, extensive inflammation is likely to cause extensive scarring
followed by contractile dysfunction and a tendency to arrhythmias.
Few of the studies mentioned previously report that LGE is a stronger predictor
of events compared to active inflammation shown by FDG-uptake. One could
speculate the following logical explanation: Sarcoid inflammation is known to have
different possible courses. In some patients, the inflammatory process is
downregulated by anti-inflammatory cytokines whereas in others the inflammation
persists. When we observe an active inflammation in PET, the patient may be on
either of those paths. When we see LGE as a marker of scarring in CMR, we know
that in that patient the inflammation has persisted long enough to cause damage and
scarring. LGE can be seen as a marker of damage, whereas FDG-uptake is (at least
in patients studied early in the course of their disease) a marker of possible future
damage.
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7 CONCLUSION
Our results add to the growing base of evidence for the important role of FDG-PET
in the workup of suspected cardiac sarcoidosis.
We identified a group of patients - females with advanced AV-block - that has a
high frequency of pathological PET-findings. In this group, FDG-PET is likely to
affect treatment decisions by demonstrating active myocardial inflammation.
Patients with a history of ventricular tachyarrhythmias had high frequency of right
ventricular FDG-uptake that was linked to adverse cardiovascular event. In these
patients, FDG-PET may be useful in deciding whether to implant an ICD to the
patient.
 Recently developed ECG parameters such as septal remodeling and inferolateral
remodeling were linked to pathological PET-findings. Our results are preliminary
but these ECG parameters may prove valuable in the initial workup of patients with
suspected cardiac sarcoidosis.
Right ventricular involvement was more frequent in patients with systemic
sarcoidosis defined by presence of pathological FDG uptake foci outside of the
heart. Endomyocardial biopsy verifying sarcoidosis was obtained from seven
patients. Six of these patients had pathological myocardial uptake, but due to small
amount of these patients the association between pathological myocardial PET-
findings and positive EMB was not significant. However, biopsy verification of
sarcoidosis was obtained more often from a tissue sample obtained from sites other
than the heart. Extracardiac FDG uptake foci in PET were significantly linked to
tissue biopsy indicating sarcoidosis.
Finally, right ventricular FDG-uptake and high total cardiac metabolic activity
were linked to high risk of adverse cardiovascular event during follow-up. These
findings have valuable use in the risk stratification of patients suspected of having
CS.
American consensus statement on the use of FDG-PET in CS suggests
performing FDG-PET in patients with unexplained AV-block and VT, and our
findings provide further proof for the utility of FDG-PET in these patient groups.
Furthermore, our results add to a growing base of evidence on the prognostic value
of FDG-PET in suspected CS.
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Background: 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) is a feasible method to investi-
gate th e inammatory activity of the myocardium in cardiac sarcoidosis. However, PET is costly and not as widely
available as standard electrocardiogram (ECG). Current ECG ndings related to cardiac sarcoidosis are highly
non-speci c. In this study, our aim was to determine whether novel ECG parameters are associated with patho-
logical PET ndings in patients with suspected cardiac sarcoidosis.
Methods: A total of 133 patients underwent cardiac FDG PET examination in Tampere University Hospital be-
tween August 2012 and September 2015. The left ventricular FDG uptake was categorized as either normal or
pathological. Additionally, in-depth analyses of resting ECG were performed. Among other parameters, the pres-
ence of septal and inferolateral remodelling was assessed. These are novel ECG parameters related to local struc-
tural changes in the myocardium.
Results: In the ECG, septal and inferolateral remodelling, as well as widespread QRS fragmentation were signi -
cantly associated with pathological left ventricular FDG uptake even if adjusted for age, sex, body mass index, un-
derlying cardiovascular disease and cardiac medication (p 0.05 for all). When all these ECG parameters wereb
combined in a logistic regression model, only septal remodelling remained independently associated with abnor-
mal left ventricular uptake (p 0.05).b
Conclusions: Our ndings show that novel ECG parameters septal and inferolateral remodelling, as well as diffuse
QRS fragmentation, are strongly associated with pathological cardiac ndings in FDG PET. Thus, the presence of
these ECG ndings may warrant the clinician to consider the possibility of cardiac sarcoidosis.
© 2017 Elsevier B.V. All rights reserved.
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1. Introduction
Sarcoid osis is a s ystemat ic, mu lt i-orga n granul omatous dis ease.
Cardiac manifestation is detected in up to 10% of sarcoidosis patients.
Howeve r, in po st-mor tem st udies, ca rdiac sarco idosis (CS ) h as been
found in 2 7 40% of s ar coidos is pa tients . CS is ass ociate d with– [ 1 , 2 ]
poor progno sis and may lead to lif e-threate ning even ts [ 3 , 4 ] . E ar ly
diagn osis is requir ed to lower the risk of atr io ventri cular (AV )
block, ventricular arrhythmias, heart failure and sudden death [5].
18
F-
Fluorod eoxygluc ose ( FDG) po sitron emis sion tom ograph y (PET ) is a
feasible method to investigate the in ammatory activity of the myocar-
dium in CS with a sensitivity and specicity of 89% and 78%, respectively
[6]. Cardiac magnetic resonance imaging (MRI) with late gadoli nium
enhan c ement ca n d etect ev en tiny sca rs cause d by CS . Howev er ,[7]
PET and cardiac MRI are costly and not as widely available as the stan-
dard electrocardi ogram ( ECG).
Structural heart disease can result in general and non-localizing ECG
changes, such as left ventricular hypertrophy (LVH), ST depression, wid-
ening of the QRS complex, and P terminal force . ECG changes in[8,9]
leads overlying affected regions can re ect regional disease processes.
For in stance, narr ow and d eep Q wa ves are typi cal in loca lized wa ll
thickening in hypertrophic cardiomyopathy [10]. A resting ECG is com-
monly accepted as a screening test for CS [11–13]. It can detect CS with a
sensitivity of 3 3–58 % and a s pecicity of 22–71% [14,15].
Generally, the pathological ndings related to CS in a stand-alone
ECG are non-speci c, but in conjunction with cardiac symptoms, nd- 
ings such as bundle branch block (BBB), ventricular arrhythmias, II or
III degree AV block , may con ta in c linically im porta nt in formati on
International Journal of Cardiology 249 (2017) 454–460
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[3,16]. Conductio n distur bances, ar rhythmias and ST/T chang es have
been described as typical ECG ndings in CS [2,17–19]. CS can affect vir-
tually any location of the conduction system, leading to left or right BBB
(complete or incomplete), AV block of any degree, and even sinus arrest.
The reported prevalence of conduction abnormalities has been in the
range of 12–62% [20–22]. Sustained or non-sustained ventricular tachy-
cardia may persist despite medical treatment and can result in sudden
death , which is the most feare d cardia c manif estati on of CS .[23,2 4]
The role of in-depth ECG analyses, such as a fragmented QRS complex,
in the diagnosis of CS is not well establish ed [25–28].
The data in regard to abnormal ECG and its association with cardiac
PETndings in sarcoidosis are very limited. Manabe et al. studied abnor-
mal ECG ndings and their relationship to myocardial FDG uptake in 50
patients with sarcoidosis and suspected cardiac involvement. Their ECG
analysis concentrated mainly on conventional parameters. Abnormal
ECG wa s associa ted with patholog ical FDG uptak e in that st udy .[29]
Roukoz et al . in vestig ated the asso ciation of fragm en ted QRS (fQRS )
and gran ulomato us myo cardit is. Ther e we re only sev en patients (of
58) with CS and fQRS in whom FDG PET was available. The location of
FDG uptake did not correlate with the location of fQRS [30].
In our institution, FDG PET is routinely utilized as part of the diagnos-
tic work-up in patients with suspected CS. The objective of this study
was to de termin e whet her a bn ormal ECG ndin gs in pati ents with
suspected CS are associated with pathological ndings in cardiac FDG
PET. Furthermore, we explored whether in-depth ECG analysis can pre-
dict abnormal FDG PET uptake.
2. Materials and methods
2.1. Study population
We retrospectively screened all cardiac PET examinations performed in Tampere Uni-
versity Hospital from August 2012 to September 2015. All cases in which the cardiologist
suspected CS were selected. We excluded those examinations in which the patient's clin-
ical data could not be obtained or if the study was performed to follow up on previously
diagnosed CS. PET examinations were also excluded if the dedicated imaging protocol,
as described below, was not followed precisely. At least one of the following symptoms
or conditions raised the clinical suspicion of CS in our population: unexplained AV block
(n = 61), ventricular (n = 39) or supraventricular (n = 13) arrhythmia, unexplained
dilated cardiomyopathy (n = 27), unexplained low ejection fraction in echocardiography
(n = 46), other echocardiographic ndings suggestive of CS (n = 53), or syncope (n =
27). Finally four patients were excluded as they did not have any available ECG examina-
tion. Altogether, there were 133 PET examinations analysed for this present study. All data
were collected retrospectively.
2.2. PET imaging
All p atien ts und erwent an i ntegr ated PE T/CT (Dis cover y STE 16, GE He althca re,
Milwaukee, WI, USA) examination. To minimize the physiological myocardial FDG uptake,
patients did not consume any carbohydrates during the day before the imaging and fasted
for 12 h before the FDG injection. Patients maintained a food diary during the diet. Patients
were also instructed to avoid heavy physical exercise to minimize the FDG uptake in skel-
etal muscle. Patients' height and weight were measured before the administration of the
radi ophar ma ceuti cal, an d th eir bloo d g lucose l e vel was tes ted to be 7 mm ol/l . Th eb
PET/CT images were acquired approximately 60 min after intravenous injection of FDG
using the Medrad® Intego PET infusion system (Bayer Medical Care Inc., Indianola, PA,
USA). The amount injected is currently based on the patient's weight (3 3.2 MBq/kg).–
Howev er, the p rotoco l was ch a nged in 2013. Prev ious ly, pat ients we r e giv en a xed
dose of 37 0 MBq. The mean inje cted ac tivity in our st udy popul ation was 3 20 MBq
(range 219 460 MBq). The imaging covered a volume of two bed positions around the–
myocardium. The total examination time for PET/CT was approximately 15 min. CT was
used for attenuation correction and accurate localization of uptake.
2.3. Analysis of PET images
PET/CT images were evaluated visually using the AW Volume Share workstation,™
version 4.6 (GE Healthcare). AW Volume Share allows automatic registration and fusion™
between two volumetric acquisitions. The image fusion provided added value to the side-
by-side interpretation. The images were analysed blinded to all clinical data after the pa-
tients were anonymized and randomized. The image analysis was performed indepen-
dently by two nuclear medicine specialists (KS and HT). Myocardial FDG uptake pattern
in the left ventricle (LV) was categorized visually as follows: none‘ ’ (no u ptake excee ding
blood pool), global diffuse‘ ’ (even uptake over the whole myocardium), (focal areas‘focal’
of uptake, other regions inactive), (focal spot/spots of uptake overlaid on‘focal on diffuse’
less intense global myocardial uptake) or diffuse non-global (faint diffuse activity on at‘ ’
least two LV walls but at least some areas of myocardium inactive, intensity of the uptake
less than that of the liver). The uptake was considered physiological if the pattern was
none, g lob al diff use or diff use non- global an d pa thologi cal if the p attern wa s fo cal or
foca l on dif fuse . Ther e were 12 cas es in which the t wo rea ders i nitial ly disa gree d on
wheth er P ET was nor mal o r path ologi cal. In th ese case s, the rea ders perf ormed re-
evaluation of the images together. The consensus achieved in the re-evaluation between
the two readers was used in the statistical analyses.
2.4. ECG analysis
One stan dard 12 lead ECG rec orded wi th a 50 mm/ s sp eed of e ach patie nt wa s
analysed manually in a systematic manner by one investigator (KN) blinded to the clinical
data. The ECG closest to the PET/CT study was used, but if this was a pacemaker ECG, a pre-
vious ECG without pacing was chosen.
Computer analysis measurements were used for the PQ interval and QRS duration.
LVH was de ned according to the Sokolow-Lyon criteria or Cornell voltage duration [31]
prod uct [QRS -dura tion (ms) × (RaVL in mm + SV 3 in mm with 6 m m ad ded for
women) . For ST se gment dep ression , we used 0.5 mm if the pat tern2 4 4 0 ] [32,3 3] 
was horizontal or descending and 1 mm if ascending in 2 adjacent leads measured at 
the J point + 60 ms . T-wave inversion was de ned as[34]  1 m m in 2 adjacent leads, ex-
cept for leads aVR and V1 .[35]
For fQRS in 2 adjacent leads, we used the de nitions by Das et al.  [36]. Septa l frag-
mentation was considered present if there was fQRS in 2 septal leads (V1-V3). We con-
sidered fragmentation of 5 ECG leads as widespread fQRS.N
For fascicular and BBB, standard criteria were used. Non-specic intraventricular con-
duction defect (NSIVCD) was dened as a QRS duration 120 ms, not ful lling criteria for
right (RBBB) or left BBB. For II or III degree AV block, we used data from the patient history
in addition to the ECG analysis data.
In ad ditio n to t he es tabli shed EC G ch anges , we us ed a rece ntly intr oduce d ECG
parameter Septal remodelling , which was de ned as one of the following present“ ” [37] 
in V1-V3: 1) pathological Q waves in 2 parallel leads, and/or 2) septal fQRS as de ned 
above, and/or 3) poor R-wave progression (R wave 3 mm) in leads V1-V3 accompaniedb
by fQRS, or disorderly distributed R-wave amplitudes, either RV2 RV3 or RV1N N RV 2 [38].
In addition, we introduced a novel ECG parameter Inferolateral remodelling“ ”, whi ch
was dened as follows: 1) fQRS in 1 inferior (II, III, aVF) and lateral (V4-V6) lead, and/or
2) Q wave (a s de ned bel ow) in 2 of th e le ads II, aV F, V4 -V6, and/ or 3) low vol tage 
(R-wa ve ampl itud e 3.5 mm) in II, III, aVF and V4- V6 . An e xa mple of EC G with bo th
septal- and inferolateral remodelling is shown in a.Fig. 1
The possibility of a lead switch was considered by assessing the morphology of the
P and S wa ves in th e preco rdial le ads, an d n o s uspici ous case s were o bserved . Any Q
wave 40 ms in duration, or 3 mm deep, or qR-ratio 0.25, in 2 parallel leads except   
lead aVR was considered pathological [39].
2.5. Statistical analyses
Chi-square and -test analyses were performed to compare categorical and continu-t
ous variables between the patients with and without pathological LV uptake, respectively.
A logistic linear regression analysis was performed to examine the independent relation-
ships between the ECG parameters and pathological PET ndings. Adjustments for age,
sex, BMI, underlying cardiovascular disease and cardiac medication were performed. Sta-
tistical analyses were performed using R software version 2.14.1.
3. Results
LV upt ake was cons idered phys iologi c al in 101 (76% ) p atients ;
83 (62%) had no detectable LV uptake, two (2%) had global diffuse up-
take and 16 (12%) had diffuse non-global uptake. In 32 (24%) patients
LV uptake was pathological. Of those patients, 27 (20%) had focal myo-
cardial uptake and ve (4%) had focal spots on diffuse myocardial back-
ground uptake. Examples of pathological focal myocardial uptake and
norma l PE T wi th no detec table up take are show n in Figs. 1b a n d 2 ,
respectively.
The clinical characteristics and ECG parameters in patients with or
without abnormal left ventricular FDG uptake are shown in Table 1. A
pathologica l PET nding was mo re common in fe male pati ents (p =
0.018). Patients with pathological FDG uptake had lower BMI than pa-
tients with a normal PET study (p = 0.022). The two groups did not sig-
ni cantly differ by age (p = 0.308) or presence of underlying cardiac
diseases (p = 0.513). Ventricular conduction defects (de ned as any
BBB), se ptal re mo dellin g, infer olatera l re modelli ng and wi desprea d
fQRS were more frequent in patients with abnormal LV uptake than in
patients with normal LV uptake (p 0.05 for all). The associations ofb
infero later al remod ellin g, wides pread fQ RS and septal remod ellin g
with LV upt a ke ar e il lustr ated in . Lef t a n terior fas cicula r bl ockFig. 3
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(LAFB) was th e only vent ricular conduc tion defect, in wh ich the
difference between the groups was signicant. The two groups did not
diffe r signi cantly wi th respe ct to PQ in terval ( p = 0.069) or QRS
width (p = 0.105). Neither did the groups differ with regard to the pres-
ence of AV block (II or III degree), Q waves, poor R-wave progression,
LVH, ST-s egment de pressi on, T-wave in versio ns or f QRS in at leas t
two adjacent leads. If data regarding AV block were derived from the
patient history, patients with abnormal FDG uptake had signi cantly
more II or III degree AV block compared to those with normal LV uptake
(p 0.001). Two patients had a pacemaker rhythm in the analysed ECG.b
Of the patients, 83 used ACE inhibitors, 87 beta blockers, 54 diuretics,
17 calcium channel blockers, 9 amiodarone and 13 immunosuppressive
medications. Neither the patients with or without abnormal FDG uptake
nor with or without novel ECG parameters septal- or inferolateral re-
modelling did signi cant ly differ by usage of cardiac or immunos up-
pressive medication (p 0.05 for both).N
Septal remodelling, inferolateral remodelling and widespread fQRS
remained signicantly associated with pathological LV uptake when ad-
justed for age, sex and BMI (p 0.05 for all,b Table 2). These associations
remained sig ni cant even if further adjusted for the usage of cardiac
medication, presence of underlying cardiac disease and the history of
II or III degree AV block (p 0.05 for all, Supplemental Table 1). Whenb
the presence of any BBB, septal remodelling, inferolateral remodelling
and widespread fQRS were entered into a logistic regression model as
independent variables, septal remod elling was the only variable signif-
icantly associated with abnormal LV uptake (p = 0.030, ).Ta ble 2
Fig. 1. a. A 54-year old female patient was evaluated for dyspnoea and arrhythmias. In echocardiography, the left ventricular diastolic diameter was normal and the ejection fraction was
slightly decreased (45%) with septal hypokinesis. Endomyocardial biopsy ndings were compatible with sarcoidosis. The ECG (50 mm/s) shows rst degre e atrioventricular block and right 
bundle branch block. Septal remodelling is evident from QRS fragmentation in leads V2-V3. In addition, QRS fragmentation is also present in leads II, III, aVL and aVF, which ful lls the
criteria for inferolateral remodelling. Pathological Q waves are present in leads I and aVL. T-wave inversions in I, aVL and V1-V6 can't be fully explained by the bundle branch block.
b. PET/CT fusion images in axial (above) and coronal (below) views of a 54-year old female patient. ECG of the same patient is shown in Fig. 1a. Pathological patchy uptake is seen in
anterior and lateral walls of the left ventricle as well as the ventricular septum and the free wall of the right ventricle.
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PET ndings with diffuse LV uptake patterns may sometimes be con-
sider ed in determin ate in regard t o CS. Ther efore, we re analyz ed th e
data of the Ta ble 2 using only patients with focal or no detectable uptake
in PET. A ll patients with global diff use, non-global diff use or focal on dif-
fuse activity patterns were excluded from this reanalysis. The results of
the rema ined esse ntiall y sim ilar (data n ot sh own). The onl yTabl e 2
exception was that none of the ECG ndings alone remained signi cant- 
ly associated with pathological PET ndings when septal remodelling,
inferolateral remodelling and widespread QRS fragmentation were all
entered into a logistic regression model as independent variables.
In our population there were seven patients with endomyocardial
biopsy (EMB) conrmed CS, six of them had pathological PET ndings.
Three of th e pati en ts with po sitive EM B h ad septa l re modelli ng and
two had infe ro latera l re modelli ng in th e ECG. H ence, ve pat ients
with sarcoidosis in EMB had either septal or inferolateral remodelling.
4. Discussion
Diagnosing CS is often challenging. Due to the inhomogeneous in-
volvement of the myocardium, the diagnostic yield of EMB is low [22],
and there is a need for more sensitive diagnostic methods. Dedicated
Fig. 2. PET/CT fusion images in axial (above) and coronal (below) views of a 19-year old
male patient. This is a normal PET nding as the myocardium does not accumulate FDG.
Table 1
Clinical characteristics and ECG parameters in patients with or without abnormal left ven-
tricular FDG uptake.
Normal
uptake
(n = 101)
Pathological
uptake
(n = 32)
p value
Age (years) 43.4 ± 19.9 46.0 ± 12.2 0.308
Body mass index (kg/m 2 ) 28.2 ± 5.8 26.1 ± 3.9 0.022
Female sex (%) 36 59 0.018
Underlying cardiac disease (%) 62 69 0.513
Cardiac medication (%) 82 72 0.207
Immunosuppressive medication (%) 7.9 15.6 0.201
PQ interval (ms) 191.7 ± 56.0 222.3 ± 79.7 0.069
QRS length (ms) 113.9 ± 27.7 124.4 ± 32.5 0.105
Q wave present (%) 1 0 0.650
Poor R wave progression (%) 20 29 0.493
Left ventricular hypertrophy (%) 25 14 0.387
ST segment depression (%) 22 21 0.959
T wave inversion (%) 37 43 0.669
QRS fragmentation (%) 60 69 0.395
Septal remodelling (%) 15 44 0.001
Inferolateral remodelling (%) 9 28 0.006
RBBB (%) 14 22 0.279
LBBB (%) 7 9 0.648
LAFB (%) 10 28 0.010
LPFB (%) 4 0 0.253
NSIVCD (%) 11 21 0.113
Any intra-ventricular conduction defect (%) 35 56 0.030
AV block (II or III degree) (%) 9 13 0.532
Widespread ( 5 leads) fQRS (%) 22 50 0.002N
AV block (II or III degree, data from patient
history) (%)
31 69 0.001b
Values are means ± SD in continuous variables and % in dichotomous variables. RBBB =
righ t ventr icul ar bu ndle b ranch bloc k, LBB B = le ft bun dle b ranch bloc k, LAFB = l eft
anterior fascicular block; LPFB = left posterior fascicular block; NSIVCD = non-speci c
intra-ventricular conduction defect, AV = atrioventricular, fQRS = QRS fragmentation.
Fig. 3. The associations of septal remodelling, inferolateral remodelling and widespread
frag mented QRS wi th lef t ve ntricu lar upta ke. ECG = elec trocar diogr am, LV = left
ventricular.
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cardiac FDG PET is a feasible method to investigate the inammatory ac-
tivity of the myocardium . However, PET is costly and not as widely[6]
available as standard ECG. In this study pathological PET ndings were
observed in all but one EMB positive CS patients. The reason for negative
PET in one patient with biopsy con rmed CS is probably related to the
fact that FDG uptake can only be seen in an active phase of the disease.
A standard resting ECG has been used to screen for CS [11 13]– , b u t
the se nsitivi ty and speci city h ave bee n report ed to be low . [14,1 5]
Recen tly, se veral new paramet ers fr om in-d epth ECG a nalyse s have
been described, and their associations with various structural heart dis-
eases have been reported. However, these parameters have not been
extensively studied in the diagnosis of CS [25–28]. N o rm data on the
relati onship be tween EC G p aramet er s a nd FDG PET in a po pulat ion
with CS suspicion exists. In a study by Manabe et al., patients with an ab-
norma l ECG, de ned as RBBB, AV b lock, le ft axis deviati on, non -
sustained ventricular tachycardia, premature ventricular contractions,
abnormal Q wave or ST-T abnormalities, had a higher number of LV seg-
ments with abnormal FDG uptake than patients with a normal ECG [29].
The authors concluded that AV block was the only specic ECG param-
eter signi cantly correlating with pathological PET ndings. To the best 
of our knowledge, our study is the rst to include the novel ECG param-
eters septal remodelling and inferolateral remodelling and to compare
ECG and cardiac PET ndings.
We did not detec t si gni c a nt diffe rences in QRS widt h or in the
presence of poor R-wave progression, LVH, ST-segment depression or
T-inversions between the patients with or without abnormal LV uptake.
This nding is pr obably rel ated to the fact that these paramete rs are
non-s peci c and m ay be associa ted with va rious car diac cond itions .
fQRS has previously been associated with CS . Interestingly[26,30,40] 
the presence of fQRS in at least two adjacent leads was not signi cantly
associated with pathological LV uptake in our study. However, fQRS is
considered to be a marker of myocardial scarring and not of in[41] am-
mation, wherea s FDG is a mark er of metabolic ac tivity. For example,
FDG accum ulation is not observed in a reas of myoca rdial inf arction
[42]. In fact, in a study by Roukoz et al., six out of seven patien ts had
no s patial corre lation bet ween F DG upt a ke and fQR S [30] . In our
study, fQRS in ve or more ECG leads was signi cantly associated with
abnormal LV uptake. We may postulate that in patients with highly ab-
normal ECG, active in ammatory lesions and more advanced myocardi-
al damage may co-exist.
CS has been associated with ventricular conduction defects, especial-
ly RBB B [22,4 0,43], but on ly a fe w stud ies hav e inve stigate d the
assoc iation of myo cardia l FDG upt ake and ventr icula r con duction
abnormalities. Ohira et al. studied FDG PET and cardiac MRI in patients
with CS and either RBBB or AV block. In their population, 72% of the pa-
tients with RBBB had pathological PET ndings. However, PET wa s m ore
likely pathological in patients with AV block (92%). The authors hypoth-
esized that compared with AV block, RBBB is a sign of more advanced
myocardial damage with scar formation [44]. O u r nding that patients
with pathological LV FDG uptake had signicantly more ventricular con-
duction abnormalities than patients with normal LV uptake is consisten t
with the literature. However, in this study, LAFB was the only ventricu-
lar conduction defect, which was signicantly associated with abnormal
PET ndings. In our population, only 32% of the patients with RBBB had
abnormal FDG uptake. The reason for the lack of association between
RBBB and abnormal LV uptake in our study, which is in contrast to the
ndings by Ohira et al., could be that our patients generally underwent
cardiac imaging at an earlier stage of the disease process with less scar
formati on. Th is assu mption seem s to gain some supp ort fro m the
description of b iological m echanisms in CS d escribed by Ohira et al.
AV b lock is con si dered a fre quent comp licati on of CS [22]; i n th e
study by Ohira et al., most of the patients (92%) with AV block (Mobitz
type II or grade III AV-block) had pathological PET ndings [44]. Also i n
the pr esent st udy, II or III -degre e AV blo ck was asso ciate d with a
pathological PET nding, if data from patient history was used. The pres-
ence of AV block in the ECG closest to the PET/CT study was not signi -
cantly associated with PET ndings. This is most likely due to the poor
sensitivity of a single EC G to detec t II degree A V block.
Contrary to established ECG parameters, such as LVH and ST/T chang-
es, the novel ECG parameters septal and inferolateral remodelling were
strongly rela ted to patho logical PETndings in th e present study. The as-
sociation remained even after adjustment for age, sex, BMI, cardiac med-
ication, other cardiac disease and patient history of II or III degree AV
block. Th e results did not esse ntially ch ange even if the possi ble indeter -
minate cases with diffuse LV uptake patterns were excluded from the
analyses. The amount of EMB- conrmed CS was low in our popula tion.
Nevertheless, ve out of seven pa t ients (71%) with CS-positive EMB had
either septal- or in ferolateral remodelling in their ECG. Th e odds ratio to
predict pathological FDG uptake was 5.9 for septal remodelling and 4.5
for the presence of II or III degree AV block in the same ECG. The fact
that AV block has been strongly related to pathological PET ndings in
previous studies underscores the clinical importance of the ECG param-
eter septal remodelling . Septal remodelling was also signi cantly[44] 
associated with abnormal LV uptake, independently of the ECG parame-
ters inferolateral remodelling and widespread fQRS.
LV remodelling is a well-established pathophysiological phenome-
non in disease s such as hyper tensiv e heart disea se, valv ular di sease
and c ardiomyo pathie s, and it h as been asso c iated with n on-spec i c
ECG changes such as LVH and ST/T abnormalities [45]. However, the as-
sociation between ECG markers of regional disease processes and struc-
tural heart disease are less well establis hed. Our re su lts su gge st tha t
these paramet ers might be re lated to a ctive in am mat ion. Althoug h
these ECG ndings by themselves are not an indication for PET and can-
not be considered diagnostic for CS, our results emphasize the potential
role of simple low cost methods in the dia gnostic work -up for CS.
Table 2
Logistic regression models for the associations between left ventricular FDG uptake and
age, sex, body mass index and selected ECG parameters.
A)
Left ventricular uptake OR 2.5% 97.5% p value
Septal remodelling 6.2453 2.3028 16.9377 0.001b
Sex 2.443 1.0047 5.9402 0.0488
Body mass index 0.9203 0.8393 1.0091 0.0771
Age 1.0241 0.9891 1.0603 0.1789
Intercept OR = 0.4165
B)
Left ventricular uptake OR 2.5% 97.5% p value
Inferolateral remodelling 3.7699 1.2905 11.0129 0.0153
Sex 2.3134 0.9834 5.442 0.0547
Body mass index 0.9269 0.8482 1.0129 0.0935
Age 1.0121 0.9791 1.0461 0.4773
Intercept OR = 0.7819
C)
Left ventricular uptake OR 2.5% 97.5% p value
Widespread ( 5 leads) QRS fragmentation 5.0885 1.9496 13.2807 0.001N b
Sex 2.9015 1.1906 7.0709 0.0191
Body mass index 0.922 0.844 1.0071 0.0714
Age 1.0273 0.9918 1.064 0.1333
Intercept OR = 0.2976
D)
Left ventricular uptake OR 2.5% 97.5% p value
Inferolateral remodelling 1.8956 0.5904 6.0864 0.2826
Widespread ( 5 leads) QRS fragmentation 2.0591 0.7961 5.3259 0.1363N
Septal remodelling 2.8971 1.1132 7.5395 0.0293
Any ventricular conduction defect 0.6223 0.2569 1.5075 0.2934
Intercept OR = 0.2151
The s elec te d EC G para meter s were se ptal r emode l ling (A), infe rolat eral r emodel ling
(B) and widespread QRS fragmentation (C). Model D included all the above-mentioned
parameters as well as the presence of any ventricular conduction defect as independent
variables. OR = odds ratio.
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There are c lear li mitation s with our s tudy. T his stu dy was cross-
secti onal, an d c ausali ty could n ot be asse ssed. Co rrespond ing to th e
majority of the Finnish population, our study group consisted of mainly
white Cauc asians, and thes e resul ts ca n not be dir ectly gener alized
to ot her pop ulation s. A ma jor li mitati on conc erning all studie s
investigatin g CS is the lack of a sensitive and speci c diag nostic gold
standard. Therefore, one cannot be certain of the underlying cause of
t h e p a t h o l o g ic a l ndi ngs. In our insti tution , myo cardial perf usion
imaging is not performed routinely. In the case of a pathological FDG
PET nding, perfusion imaging might improve diagnostic accuracy . [6]
However, in this particular study, we only explored the PET ndings;
perfusion imaging would not have changed thei r categoriz ation. In a
recen t stu dy, 72 h of ve ry low carb ohydrat e die t wa s re ported to be
more ef cient in minimizing the physiologic FDG uptake of the myocar-
dium in compa ri son to 24 h of die t . On th e ot her hand, if a[ 4 6 ]
prolon ged diet ha d been us ed in this stu dy, some of th e pat ients
would probably have been excluded due to the failure in following the
protocol precisely. There were 12 cases in which the initial conclusion
diffe red betwee n the two PE T in terpre ters. Howe ver, in su ch cases ,
consen sus betwee n the rea ders was ac hieved an d us ed in stati stical
analy ses. Su boptim al in ter-re ader va riabi lity h as be en re p orted
previously [47].
In conclusion, our ndings show that novel ECG parameters of ven-
tricular rem odelling and diffuse Q RS fragmentation are stron gly associ-
ated with pathological myocardial FDG uptake in a Finnish population
with clinical suspicion of CS. Although the relationships of these novel
ECG para meters wit h CS and thei r cli nical s igni ca nce needs to b e
furth er stu died in other popu lation s, the pres en ce of these ECG
ndings may warrant the clinician to consider the possibility of cardiac
sarcoidosis.
Supp leme ntar y d ata t o thi s art icle c an be f ound onli ne a t http://dx.
doi.org/10.1016/j.ijcard.2017.07.027.
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Introduction. In up to 65% of cardiac sarcoidosis patients, the disease is conﬁned to the
heart. Diagnosing isolated cardiac sarcoidosis is challenging due to the low sensitivity of
endomyocardial biopsy. If cardiac sarcoidosis is part of biopsy-conﬁrmed systemic sarcoidosis,
the diagnosis can be based on cardiac imaging studies. We compared the imaging features of
patients with isolated cardiac FDG uptake on positron emission tomography with those who
had ﬁndings indicative of systemic sarcoidosis.
Materials and methods. 137 consecutive cardiac FDG-PET/CT studies performed on sub-
jects suspected of having cardiac sarcoidosis were retrospectively analyzed.
Results. 33 patients had pathological left ventricular FDG uptake, and 12 of these also had
pathological right ventricular uptake. 16/33 patients with pathological cardiac uptake had
pathological extracardiac uptake. 10/12 patients with both LV- and RV-uptake patterns had
extracardiac uptake compared to 6/21 of those with pathological LV uptake without RV uptake.
SUVmax values in the myocardium were higher among patients with abnormal extracardiac
uptake. The presence of extracardiac uptake was the only imaging-related factor that could
predict a biopsy indicative of sarcoidosis.
Conclusion. Right ventricular involvement seems to be more common in patients who also
have ﬁndings suggestive of suspected systemic sarcoidosis, compared with patients with PET
ﬁndings indicative of isolated cardiac disease. (J Nucl Cardiol 2018)
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Abbreviations
CS Cardiac sarcoidosis
FDG Fluorodeoxyglucose
PET Positron emission tomography
SUVmax Maximum standardized uptake
LV Left ventricle
RV Right ventricle
EMB Endomyocardial biopsy
LVEF Left ventricular ejection fraction
INTRODUCTION
Sarcoidosis is a multisystem granulomatous inﬂam-
matory disorder that can affect any organ system. The
disease typically manifests in the lungs, often as
asymptomatic hilar lymph node enlargement. The most
common presentation is symmetric hilar adenopathy,
which is encountered in approximately 95% of patients
with lung sarcoidosis.1 Middle mediastinal or prevascu-
lar lymph nodes are involved in approximately 50% of
patients with pulmonary sarcoidosis.2 Unilateral hilar
lymph node enlargement or mediastinal node enlarge-
ment without hilar adenopathy indicates an alternative
etiology.3 Pulmonary sarcoidosis is often an incidental
ﬁnding when imaging is performed to investigate other
symptoms or diseases. Sarcoidosis patients should be
screened for cardiac involvement because of the poten-
tial life-threatening consequences of the disease. Sudden
cardiac death has been shown to be a potential initial
manifestation of CS.4–6 The recommended initial
screening evaluations include patient medical history,
ECG, and echocardiography. However, only from 40 to
50% of patients with cardiac involvement at autopsy had
clinically evident cardiac disease during their lifetimes.7
Due to the difﬁculty of diagnosing CS, the epi-
demiological literature on the topic is limited. CS has
traditionally been diagnosed using the guidelines issued
in 2006 by the Japanese Ministry of Health and Welfare
(JMHW) and revised by the Japan Society of Sarcoido-
sis and Other Granulomatous Disorders. The revised
criteria were proposed by the Heart Rhythm Society in
2014.8 According to both guidelines, CS can only be
diagnosed via direct conﬁrmation by endomyocardial
biopsy (EMB) or based on a previous diagnosis of
systemic sarcoidosis combined with clinical and imag-
ing ﬁndings indicating cardiac involvement. Given that
the sensitivity of EMB is low, many patients with
probable CS do not fulﬁll the current diagnostic
criteria.9
Cardiac 18ﬂuorodeoxyglucose positron emission
tomography/computerized tomography (18FDG PET/
CT) (later referred to as PET) has been used to identify
active cardiac inﬂammation, with a sensitivity and
speciﬁcity of 89% and 78%, respectively.10 In the
revised JMHW guidelines, gallium-scintigraphy was
included as a major criterion to demonstrate myocardial
inﬂammation. Due to the low sensitivity of Ga-scintig-
raphy, the JMHW has since approved substituting it with
FDG-PET. The demand for cardiac imaging has
increased because it has been suggested that CS should
be excluded in patients under the age of 55 years with
unexplained dilated cardiomyopathy, second- or third-
degree atrioventricular (AV) block or persistent ventric-
ular tachycardia (VT).8,11
In a previous study of 110 Finnish CS patients, CS
was diagnosed by direct EMB in 50% of the patients and
by biopsy from another affected site combined with
cardiac imaging ﬁndings suggesting sarcoid involve-
ment in the other 50% of the patients.12 Seventy-one of
the 110 patients had clinically isolated cardiac sarcoido-
sis, e.g., no clinical signs or history suggesting
extracardiac disease. However, PET showed metaboli-
cally active mediastinal lymph nodes in 71% of these
patients. In a study by Simonen et al., it was found that
conﬁrmed CS FDG-avidity of mediastinal lymph nodes
was caused by granulomatous inﬂammation in all
patients from whom a biopsy was obtained.13 Mediasti-
nal lymph node biopsy serves as an alternative to
histologically diagnosed sarcoidosis when an EMB is
negative despite a strong clinical suspicion of CS. This
fact may increase the true clinical sensitivity of PET
compared to the ﬁgures reported previously, many of
which are based on cardiac uptake patterns only.10
Our aim was to study the association between
pathological extracardiac and cardiac FDG uptake.
MATERIALS AND METHODS
Study Population
We retrospectively screened all cardiac PET studies
performed in the Tampere University Hospital from August
2012 to September 2015. We excluded PET studies in which
the clinical indication was not CS suspicion, the patient’s
clinical data could not be obtained or the PET study was
performed to followup on previously diagnosed CS. Imaging
studies were also excluded if the dedicated imaging protocol,
as described below, was not followed precisely. Altogether,
137 PET examinations were analyzed for the present study. In
our hospital, PET is routinely performed in the diagnostic
workup of possible CS. The reason for a clinical suspicion of
CS was one or more of the following: unexplained AV block
(n = 61), ventricular (n = 39) or supraventricular (n = 13)
arrhythmia, unexplained dilated cardiomyopathy (n = 27), an
unexplained low ejection fraction on echocardiography
(n = 46), other echocardiographic ﬁndings suggestive of CS
(n = 53), or syncope (n = 27). Symptoms and clinical ﬁndings
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were considered unexplained by the cardiologist after incon-
clusive routine studies, including clinical examination, ECG
and echocardiography. Coronary angiography was performed
in cases of clinical suspicion of coronary artery disease.
PET Imaging
All patients underwent an integrated PET/CT (Discovery
STE 16, GE Healthcare, Milwaukee, WI, USA) examination.
To minimize physiological myocardial FDG uptake, the
patients were instructed not to consume any carbohydrates
during the day before the imaging exam and to fast for
12 hours before the FDG injection. The patients maintained a
food diary during the prescribed diet. The patients were also
instructed to avoid heavy physical exercise to minimize FDG
uptake in skeletal muscle. Patient height and weight were
measured before the administration of the radiopharmaceuti-
cal, and blood glucose levels were tested to conﬁrm level
of\ 7 mmol/L. The PET/CT images were acquired approx-
imately 60 min after the intravenous injection of FDG using
the Medrad Intego PET infusion system (Bayer Medical Care
Inc., Indianola, PA, USA). In our hospital, the activity injected
is based on a patient’s weight (3 to 3.2 MBq/kg). The imaging
protocol has been described in more detail previously.14
Analysis of PET Images
We classiﬁed the uptake pattern in the left ventricular
(LV) myocardium according to the recommendations of the
Japanese Society of Nuclear Cardiology (10) as ‘none’ (no
activity exceeding normal blood pool activity), ‘global diffuse’
(uniform activity over the entire myocardium), ‘focal’ (focally
increased spot(s) of activity, other regions inactive), ‘focal on
diffuse’ (intense focal spot(s) of activity overlapping global
myocardial activity) or ‘diffuse non-global’ (faint activity on at
least two LV walls, but at least some areas of myocardium with
no activity over normal blood pool activity). Diffuse non-
global uptake is not mentioned in the Japanese Society of
Nuclear Cardiology recommendations but was considered to
be a similar physiological phenomenon to diffuse uptake. The
uptake was called physiological if it was classiﬁed as none,
global diffuse or diffuse non-global. Uptake was called
pathological if it was classiﬁed as focal or focal on diffuse.
We also classiﬁed the uptake in the right ventricle (RV) in a
similar manner. The maximum standardized uptake value
(SUVmax) in the heart was measured, and its location was
determined. Extracardiac uptake in the lymph nodes was
considered pathological if it exceeded that of the mediastinal
blood pool. The areas inspected for possible pathological
extracardiac uptake included lymph nodes in axillary, sub-
clavicular, mediastinal, hilar, and epigastric sites. Pathological
FDG uptakes in the lung parenchyma, liver, spleen, and bone
were also noted. Uptakes in the liver, spleen, and lung
parenchyma were considered pathological if there were spots
of metabolic activity exceeding the physiological uptake of the
surrounding parenchyma. Bone marrow uptake was considered
pathological if focal uptake exceeding that of the liver was
noted. The images were interpreted after patient
anonymization and randomization. The images were separately
interpreted by two experienced nuclear medicine physicians
(HT, KS) blinded to all clinical data. In cases where the
interpretation of LV uptake differed between the observers, a
consensus was reached and used in further analyses.
Collection of Clinical Data
Clinical data were retrospectively collected from the
electronic medical record system of Tampere University
Hospital, which contains information from the year 2008
onward. We collected demographic information, echocardio-
graphy ﬁndings, relevant diagnoses, symptoms, and EMB
ﬁndings.
Statistical Methods
Statistical analyses were performed using IBM SPSS
statistics version 22.0 (Armonk, NY, USA) and R software
version 3.2.2. The Chi-squared test was used for dichotomous
variables, and a t test was used for continuous variables to
compare the results. Linear regression was used to assess
independent predictors of positive biopsy ﬁndings in a mul-
tivariate model, including age, sex, and pathological LV, RV,
and extracardiac uptakes.
RESULTS
Thirty-three of 137 (24%) patients had pathological
cardiac uptake. Of these 12 (36%) had pathological
uptake in both the left and right ventricles. There were
29 of 137 (21%) patients with pathological extracardiac
uptake foci. Extracardiac uptake was signiﬁcantly asso-
ciated with pathological LV and RV uptakes (Table 1,
Figure 1). Patients with both pathological cardiac and
extracardiac uptakes had signiﬁcantly higher SUVmax
values in the myocardium compared to the patients with
abnormal myocardial uptake but physiological extrac-
ardiac uptake (SUVmax 10.4 (S.D. 4.7) and 6.6 (S.D.
2.3), respectively, P-value .001). The difference
remained signiﬁcant using SUVmax values normalized
for mediastinal bloodpool: relative SUVmax 6.4 (SD
3.3) and 4.0 (SD 1.4), respectively, P-value .008)
(Figure 2; Table 2).
Patients with uptakes in both ventricles had patho-
logical extracardiac uptake signiﬁcantly more often than
patients with physiological RV uptake (P\ .001). Ten
of the 12 patients with pathological RV uptake also had
pathological extracardiac foci. Patients with pathologi-
cal RV uptake also had pathological extracardiac uptake
more often than those with pathological uptake in the
LV but not in RV (P-value .003, Table 3, Figure 1).
Pathological myocardial uptake was associated with
uptake in mediastinal and hilar lymph nodes but not with
pathological uptake at other extracardiac sites (Table 2).
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Patients with pathological extracardiac uptake were
predominantly female, more often had a history of
ventricular tachycardia and less often had a history of
heart failure compared to the patients without patholog-
ical extracardiac uptake. Patients with pathological
extracardiac uptake had lower brain natriuretic peptide
(BNP)-values than those with no pathological extracar-
diac uptake (751 and 1698 ng/L, respectively,
P = .014).
Biopsies from an extracardiac focus were obtained
from 25 patients, which was indicative of sarcoidosis in
15 patients. In addition, 7 patients had a positive EMB.
Patients with a positive biopsy (EMB or extracardiac)
had more often pathological LV uptake, RV and
extracardiac uptake than those with no biopsy-proven
sarcoidosis (48% and 20%, P-value .009, 29% and 5%,
P-value .003, 67 and 13%, P-value\ .001, respec-
tively). However, in a multiple regression model, only
extracardiac uptake, but not LV or RV uptake, predicted
a positive biopsy overall (EMB or extracardiac). Out of
ten patients with both abnormal RV and extracardiac
uptake, six had biopsy-conﬁrmed sarcoidosis: three by
EMB and three by extracardiac tissue biopsy.
DISCUSSION
We found a signiﬁcant association between patho-
logical myocardial FDG uptake and pathological uptake
in hilar and mediastinal lymph nodes. The association
was especially strong in patients with pathological
uptake in the RV free wall. Pathological myocardial
uptake was stronger in patients who also had patholog-
ical extracardiac uptake. Extracardiac uptake was the
only factor that could predict a positive biopsy ﬁnding
for sarcoidosis.
A few studies have examined the association
between cardiac and extracardiac FDG uptakes in
patients suspected for CS, but the results are somewhat
contradictory. In a study by Kandolin et al., 71% of
patients with histologically veriﬁed CS had positive
mediastinal lymph nodes on whole-body FDG-PET.12
The percentage was the same even in patients without
clinical or anamnestic extracardiac sarcoidosis. In our
clinical population consisting of patients, who were
suspected of having CS, 29 of 137 patients (21%) had
abnormal extracardiac FDG uptake. The low number of
patients with pathological extracardiac uptake is due to
the fact that only a small proportion of our population
had sarcoidosis. In the study of Yokoyama et al.,
abnormal extracardiac uptake was observed in 54% of
the 92 FDG-PET studies performed on patients sus-
pected of having CS.15 In their population, there was a
signiﬁcantly higher proportion of biopsy-conﬁrmed CS
patients compared to our study cohort. Therefore, this
discrepancy could simply indicate selective differences
between the cohorts. In our study, a total of 33 patients
Table 1. Baseline variables and FDG-PET ﬁndings in patients with and without pathological extracar-
diac FDG uptake
Variable
Pathological
extracardiac FDG
uptake
(n = 29)
No pathological
extracardiac FDG
uptake
(n = 108) P-value
Female gender 19 (66%) 40 (37%) .006*
BMI 27.3 (4.2) 28.0 (5.9) .525
Age, years 44.1 (12.3) 44.2 (13.2) .97
History of
Ventricular tachycardia 21 (72%) 54 (50%) .035*
2nd or 3rd degree AV-block 14 (48%) 42 (39%) .241
Heart failure 8 (28%) 59 (55%) .01*
Pathological LV uptake 16 (55%) 13 (12%) \ .001*
Pathological RV uptake 10 (34%) 2 (1,9%) \ .001*
Extracardiac biopsy positive for sarcoidosis 11 (38%) 4 (4%) \ .001*
EMB or extracardiac biopsy positive for
sarcoidosis
15 (52%) 7 (7%) \ .001*
The values represent n (%) for dichotomous variables and the mean (± SD) for continuous variables
BMI, Body mass index; EMB, endomyocardial biopsy; FDG-PET, 18Fluorodeoxyglucose positron emission tomography; AV, atri-
oventricular; RV, right ventricle; LV, left ventricle
*p\0.05
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had pathological cardiac uptake, and among these
patients, 48% had abnormal extracardiac FDG uptake.
In the study of Patel et al., similar results were found. In
their study, among patients with pathological myocar-
dial uptake, 40% also had pathological extracardiac
FDG-positive foci.16 On the other hand, Blankstein et al.
reported that extracardiac FDG uptake was not signif-
icantly associated with pathological cardiac ﬁndings.17
In that study, 118 PET studies were performed to assess
myocardial inﬂammation or perfusion defects in patients
suspected of having CS, and 27% of 71 patients with
pathological uptake or perfusion defects had abnormal
extracardiac uptake. However, the authors did not
speciﬁcally report the number of patients with abnormal
cardiac uptake who also had extracardiac uptake. Per-
fusion defects may be due to previously active
inﬂammation that has since become inactive, which
may possibly explain these differing results.
There may be some alternative explanations for the
association between abnormal FDG uptakes in the RV
and in mediastinal lymph nodes in addition to their
vulnerability to sarcoid inﬂammation. Pulmonary hyper-
tension has been shown to increase FDG uptake in the
right ventricular free wall.18 Hilar adenopathy in sar-
coidosis has been associated with elevated pulmonary
pressure.19 Therefore, pulmonary hypertension and the
consequent right-ventricular workload could theoreti-
cally explain the association between abnormal FDG
uptake in mediastinal lymph nodes and in the RV.
However, pulmonary hypertension has been shown to
occur in less than 10% of patients with sarcoidosis.20
Moreover, in the context of an increased workload, the
uptake should be uniform rather than patchy as in our
patients. Also, patients with pathological RV uptake did
not have decreased LV uptake signiﬁcantly more often
than patients with no RV uptake (58% vs 55%,
All paents 
n=137
Pathological 
cardiac uptake
n=33 
LV+
RV+ 
n=12
LV+
RV+ 
EC+ 
n=10
Biopsy
posive for 
sarcoidosis 
60% (n=6)
LV+ 
RV+
EC- 
n=2
Biopsy
posive for 
sarcoidosis 
50% (n=1)
LV+
RV- 
n= 21
LV+
RV- 
EC+ 
n=6
Biopsy
posive for 
sarcoidosis 
33 % (n=2)
LV+
RV- 
EC- 
n=15
Biopsy
posive for 
sarcoidosis 
13 % (n=2)
No pathological 
cardiac uptake
n=104
LV- 
RV- 
EC+ 
n=13
Biopsy
posive for 
sarcoidosis 
54 % (n=7)
LV- 
RV- 
EC- 
n=91
Biopsy
posive for 
sarcoidosis 
4 % (n=4)
Figure 1. Patients divided into groups according to PET ﬁndings and the number of tissue biopsies
positive for sarcoidosis. LV, left ventricle; RV, right ventricle; EC, extracardiac; ?, pathological
FDG uptake; -, no pathological FDG uptake.
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respectively, P-value .542). In our cohort, 8 of 12
patients with abnormal RV uptake also had abnormal
FDG uptake in hilar lymph nodes. Interestingly, in our
study population, no patients had abnormal RV uptake
without accompanying LV uptake. There are only a few
case reports of isolated right ventricular CS, and only
one patient showed this pattern in the study of Manabe
et al.21–23 One could also speculate that cardiac sar-
coidosis typically begins in the LV, which has the
greatest myocardial mass of the heart chambers, and the
right ventricle and mediastinal lymph nodes would then
become involved later if inﬂammation starts to spread.
This speculation could explain why the association was
especially strong between abnormal extracardiac and
RV uptakes in our study.
Previously, Manabe et al. showed that patients with
pathological RV uptake fulﬁll the JMWH criteria more
often than those with uptake only in the LV.22 This is
Figure 2. Fusion and MIP images of patients with pathological FDG uptake in left ventricle, right
ventricular free wall, and mediastinal lymph nodes (above) and with uptake only in ventricular
septum (below).
Table 2. Pathological uptakes at different extracardiac sites in patients with myocardial uptake in both
ventricles and in the left ventricle only
Extracardiac
uptake site
Pathological LV uptake with no
RV uptake (n = 21)
Pathological uptake in both
ventricles (n = 12)
P-
value
Lung 3 (14%) 3 (25%) .374
Spleen 0 (0%) 1 (8%) .364
Hilar ln 6 (29%) 8 (67%) .039*
Mediastinal ln 6 (29%) 8 (67%) .039*
Axillary ln 0 (0%) 0 (0%)
Subclavicular ln 0 (0%) 1 (8%) .364
Abdominal ln 1 (5%) 0 (0%) .636
The values are n (%)
RV, right ventricle; LV, left ventricle; ln, lymph node
*p\0.05
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consistent with our ﬁndings: 6 of 12 patients with RV
uptake had biopsy-conﬁrmed sarcoidosis compared to
only 4 of 21 patients with LV uptake alone. As the
diagnostic yield of EMB is low, extracardiac uptake foci
provide an alternative site for biopsy. Manabe et al. also
showed that patients with RV uptake had more wide-
spread pathological uptake in the LV, suggesting more
widespread disease. All these ﬁndings seem to suggest
that the inﬂammatory process is more widespread in
patients with RV involvement, and one may speculate
that sarcoidosis of the heart originates in the LV.
We did not ﬁnd a statistically signiﬁcant association
between abnormal cardiac FDG uptake and non-hi-
lar/mediastinal extracardiac uptake. The low statistical
power due to the low number of extrathoracic FDG-avid
foci may explain this result. On the other hand, PET
results indicated lung sarcoidosis in 14 patients. Abnor-
mal FDG uptake in the lung parenchyma was not
Table 3. Pathological extracardiac uptakes at different sites in patients with and without pathological
LV uptake, RV uptake, and LV uptake without RV uptake (a, b, and c, respectively)
Extracardiac
uptake site
Pathological LV
uptake (n = 33)
Physiological cardiac
uptake (n = 104) P-value
3a
Lung 6 (18%) 8 (7.7%) .085
Spleen 1 (3%) 4 (4%) .652
Hilar ln 14 (42%) 10 (10%) \ .001*
Mediastinal ln 14 (42%) 9 (9%) \ .001*
Axillary ln 0 (0%) 5 (5%) .246
Subclavicular ln 1 (3%) 4 (4%) .652
Abdominal ln 1 (3%) 5 (5%) .554
Extracardiac
uptake site
Pathological RV
uptake (n = 12)
Physiological RV
uptake (n = 125) P-value
3b
Lung 3 (25%) 11 (9%) .108
Spleen 1 (8%) 4 (3%) .372
Hilar ln 8 (67%) 16 (13%) \ .001*
Mediastinal ln 8 (67%) 15 (12%) \ .001*
Axillary ln 0 (0%) 5 (4%) .628
Subclavicular ln 1 (8%) 4 (3%) .372
Abdominal ln 0 (0%) 6 (5%) .571
Extracardiac
uptake site
Pathological LV
uptake with no RV uptake (n = 21)
Physiological cardiac
uptake (n = 104) P-value
3c
Lung 3 (14%) 8 (8%) .273
Spleen 0 (0%) 4 (4%) .474
Hilar ln 6 (29%) 10 (10%) .029*
Mediastinal ln 6 (29%) 9 (9%) .020*
Axillary ln 0 (0%) 5 (5%) .628
Subclavicular ln 0 (0%) 4 (4%) .372
Abdominal ln 1 (5%) 5 (5%) .735
The values are n (%)
RV, right ventricle; LV, left ventricle; ln, lymph node
*p\0.05
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associated with abnormal LV or RV uptake. Patients
with known lung sarcoidosis may be promptly referred
for PET when presenting with unspeciﬁc symptoms
considered potentially cardiac in origin. This could lead
to a selection bias toward imaging patients with less-
severe symptoms/ﬁndings if they have known lung
sarcoidosis.
In our population, a positive tissue biopsy for
sarcoidosis was obtained signiﬁcantly more often from
patients with extracardiac uptake than from those who
had physiological extracardiac uptake. This ﬁnding was
expected, as a tissue biopsy is easier to obtain from
extracardiac sites compared to EMB. Seven patients had
biopsy conﬁrmation of sarcoidosis but physiological
cardiac uptake on PET, which is most likely due to the
inactive state of their sarcoid disease. As shown in our
previous study, one patient with EMB-conﬁrmed CS did
not have any myocardial uptake on PET.14 Such a
ﬁnding may represent a patient with myocardial inﬂam-
mation that has caused myopathy that has since become
inactive and accordingly PET-negative.
Our results and the previous literature seem to
suggest that truly isolated CS is often conﬁned to the LV
myocardium. According to the present diagnostic crite-
ria, EMB is the only method to verify isolated CS.
However, EMB is rarely obtained from the LV. There-
fore, if the patients in our population with pathological,
isolated LV uptake truly have CS, then the present
diagnostic criteria are insensitive for the diagnosis of
isolated CS.
There are limitations in our study. Guidelines to
select patients with suspected CS for PET imaging did not
exist until very recently.24 Our study population is
relatively unselected, with most cases showing PET- or
biopsy-negative results. However, this represents the true
clinical situation. Perfusion imaging might improve
diagnostic accuracy in the case of pathological PET
ﬁndings. However, in our institution, it is not routinely
performed in combination with cardiac PET. Further-
more, our study dealt with PET only, and perfusion
imaging would not have changed the categorization of the
ﬁndings. Our study population consists of Finnish patients
representing Caucasians. Since the epidemiology of
sarcoidosis is known to differ between populations, our
ﬁndings may not be directly generalizable to other
populations. In addition, the number of patients with
biopsy-conﬁrmed cardiac sarcoidosis in our population
was relatively low. This limitation in statistical power is
evident in many of the available CS studies.
NEW KNOWLEDGE GAINED
Right ventricular involvement seems to be more
common in patients who have FDG-PET ﬁndings
suggestive of systemic sarcoidosis compared to those
with pathological ﬁndings conﬁned to the heart.
CONCLUSION
Patients with pathological myocardial FDG uptake
had abnormal FDG uptake in mediastinal and hilar lymph
nodes more often than patients with physiological cardiac
uptake. Patients with both LV and RV uptakes had FDG
uptake in mediastinal and hilar lymph nodes more often
than thosewith isolated LVuptake. SUVmax values in the
myocardium were higher in the patients with abnormal
extracardiac FDG uptake, suggesting that sarcoid inﬂam-
mation in the heart is stronger and more widespread in
patients with ﬁndings suggestive of systemic sarcoidosis.
Disclosures
Heikki Tuominen, Atte Haarala, Antti Tikkakoski, Mika
Ka¨ho¨nen, Kjell Nikus, Kalle Sipila¨ declare that they have no
conflict of interest.
References
1. Henke CE, Henke G, Elveback LR, Beard CM, Ballard DJ, Kur-
land LT. The epidemiology of sarcoidosis in Rochester,
Minnesota: A population-based study of incidence and survival.
Am J Epidemiol 1986;123:840-5.
2. Brauner MW, Grenier P, Mompoint D, Lenoir S, de Cremoux H.
Pulmonary sarcoidosis: Evaluation with high-resolution CT.
Radiology 1989;172:467-71.
3. Iannuzzi MC, Fontana JR. Sarcoidosis: Clinical presentation,
immunopathogenesis, and therapeutics. JAMA 2011;305:391-9.
4. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am
Heart J 2009;157:9-21.
5. Fleming HA, Bailey SM. The prognosis of sarcoid heart disease in
the united kingdom. Ann N Y Acad Sci 1986;465:543-50.
6. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of
long-term survival in Japanese patients with cardiac sarcoidosis
treated with prednisone. Am J Cardiol 2001;88:1006-10.
7. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A
morphologic study of 38 autopsies with clinicopathologic corre-
lations. Arch Pathol Lab Med 1995;119:167-72.
8. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus
statement on the diagnosis and management of arrhythmias asso-
ciated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-23.
9. Kandolin R, Lehtonen J, Graner M, et al. Diagnosing isolated
cardiac sarcoidosis. J Intern Med 2011;270:461-8.
10. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in
the diagnosis of cardiac sarcoidosis: A systematic review and
metaanalysis including the Ontario experience. J Nucl Med
2012;53:241-8.
11. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant
cell myocarditis as causes of atrioventricular block in young and
middle-aged adults. Circ Arrhythm Electrophysiol 2011;4:303-9.
12. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis:
Epidemiology, characteristics, and outcome over 25 years in a
nationwide study. Circulation 2015;131:624-32.
Tuominen et al Journal of Nuclear Cardiology
18-FDG-PET in a patient cohort suspected for cardiac sarcoidosis
13. Simonen P, Lehtonen J, Kandolin R, et al. F-18-ﬂuorodeoxyglu-
cose positron emission tomography-guided sampling of
mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis.
Am J Cardiol 2015;116:1581-5.
14. Tuominen H, Haarala A, Tikkakoski A, et al. 18F-FDG-PET in
ﬁnnish patients with clinical suspicion of cardiac sarcoidosis:
Female sex and history of atrioventricular block increase the
prevalence of positive PET ﬁndings. J Nucl Cardiol 2017. https://
doi.org/10.1007/s12350-017-0940.
15. Yokoyama R, Miyagawa M, Okayama H, et al. Quantitative
analysis of myocardial 18F-ﬂuorodeoxyglucose uptake by PET/CT
for detection of cardiac sarcoidosis. Int J Cardiol 2015;195:180-7.
16. Patel DC, Gunasekaran SS, Goettl C, Sweiss NJ, Lu Y. FDG PET-
CT ﬁndings of extra-thoracic sarcoid are associated with cardiac
sarcoid: A rationale for using FGD PET-CT for cardiac sarcoid
evaluation. J Nucl Cardiol 2017. https://doi.org/10.1007/s12350-
017-0962-4.
17. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emis-
sion tomography enhances prognostic assessments of patients with
suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36.
18. Oikawa M, Kagaya Y, Otani H, et al. Increased [18F]ﬂuo-
rodeoxyglucose accumulation in right ventricular free wall in
patients with pulmonary hypertension and the effect of epopros-
tenol. J Am Coll Cardiol 2005;45:1849-55.
19. Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D,
Hill NS. Vasoresponsiveness of sarcoidosis-associated pulmonary
hypertension. Chest 2001;120:866-72.
20. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hyper-
tension and its clinical relevance in patients with sarcoidosis.
Chest 2006;129:1246-52.
21. Mohsen A, Panday M, Wetherold S, Jimenez A. Cardiac sar-
coidosis mimicking arrhythmogenic right ventricular dysplasia
with high deﬁbrillation threshold requiring subcutaneous shocking
coil implantation. Heart Lung Circ 2012;21:46-9.
22. Manabe O, Yoshinaga K, Ohira H, et al. Right ventricular (18)F-FDG
uptake is an important indicator for cardiac involvement inpatientswith
suspected cardiac sarcoidosis. Ann Nucl Med 2014;28:656-63.
23. Hernandez Pampaloni M, Nazer B, Botvinick E. Isolated right
ventricular cardiac sarcoidosis demonstrated by (1)(8)FDG posi-
tron emission tomography. J Nucl Cardiol 2014;21:652-4.
24. Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-
ASNC expert consensus document on the role of 18F-FDG PET/
CT in cardiac sarcoid detection and therapy monitoring. J Nucl
Cardiol 2017;58:1341-53.
Journal of Nuclear Cardiology Tuominen et al
18-FDG-PET in a patient cohort suspected for cardiac sarcoidosis

ORIGINAL ARTICLE
FDG-PET in possible cardiac sarcoidosis: Right
ventricular uptake and high total cardiac
metabolic activity predict cardiovascular events
Heikki Tuominen, MD,a Atte Haarala, MD, PhD,a Antti Tikkakoski, MD,a
Mika Ka¨ho¨nen, MD, PhD,a,b Kjell Nikus, MD, PhD,b,c and Kalle Sipila¨, MD, PhDa
a Department of Clinical Physiology and Nuclear Medicine, Tampere University Hospital,
Tampere, Finland
b Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
c Department of Cardiology, Heart Center, Tampere University Hospital, Tampere, Finland
Received Dec 7, 2018; accepted Feb 1, 2019
doi:10.1007/s12350-019-01659-2
Background. Cardiac involvement accounts for the majority of morbidity and mortality in
sarcoidosis. Pathological myocardial ﬂuorodeoxyglucose (FDG)-uptake in positron emission
tomography (PET) has been associated with cardiovascular events and quantitative metabolic
parameters have been shown to add prognostic value. Our aim was to study whether the
pattern of pathological cardiac FDG-uptake and quantitative parameters are able to predict
cardiovascular events in patients with suspected cardiac sarcoidosis (CS).
Methods. 137 FDG-PET examinations performed in Tampere University Hospital were
retrospectively analyzed visually and quantitatively. Location of pathological uptake was noted
and pathological metabolic volume, average standardized uptake value (SUV), and total cardiac
metabolic activity (tCMA) were calculated. Patients were followed for ventricular tachycardia,
decrease in left ventricular ejection fraction, and death.
Results. Eleven patients had one or more cardiovascular events during the follow-up. Five
patients out of 12 with uptake in both ventricles had an event during follow-up. Eight patients
had high tCMA (> 900 MBq) and three of them had a cardiovascular event. Right ventricular
uptake and tCMA were signiﬁcantly associated with cardiovascular events during follow-up (P-
value .001 and .018, respectively).
Conclusions. High tCMA and right ventricular uptake were signiﬁcant risk markers for
cardiac events among patient with suspected CS. (J Nucl Cardiol 2019)
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LV Left ventricle
RV Right ventricle
CV Cardiovascular
LVEF Left ventricular ejection fraction
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INTRODUCTION
Detecting cardiac involvement in sarcoidosis is
essential, as it accounts for the majority of sarcoidosis-
related deaths.1–3 Cardiac 18ﬂuorodeoxyglucose positron
emission tomography/computerized tomography
(18FDG PET/CT) (later referred to as PET) has been
used to identify active cardiac inﬂammation with a
sensitivity and speciﬁcity of 89% and 78%,
respectively.4
In early studies, the prognosis of cardiac sarcoidosis
(CS) was poor and resulted in death within 2 years.5
Later studies showed an overall improvement of prog-
nosis. In a nationwide Finnish study of 110 CS patients,
9% died during a median follow-up of 79 months.6 Left
ventricular ejection fraction (LVEF) was the most
powerful prognostic factor in CS patients treated with
corticosteroids.7 It is essential to start corticosteroid
treatment early, as recovery of left ventricular function
is more pronounced in patients with only moderately
decreased LVEF. In patients with LVEF\ 30%, corti-
costeroid therapy did not improve cardiac function.8 In
addition to degrading function, CS may also cause
ventricular arrhythmias, sometimes with fatal
consequences.9–11
Existing literature on the prognostic value of PET is
relatively scarce, but it has been shown to enhance the
prognostic assessment of CS beyond the Japanese
Ministry of Health and Welfare (JMWH) criteria.12,13
According to Ahmadian et al., total cardiac metabolic
activity (tCMA) independently predicted cardiac events
in patients with previously diagnosed sarcoidosis.14 On
the other hand, a study comparing ﬁndings in consec-
utive PET- and cardiac magnetic resonance imaging
(CMR) studies reported no prognostic value of PET-
ﬁndings among patients with late gadolinium enhance-
ment (LGE) in CMR.15
Our aim was to study how visual and quantitative
PET-imaging parameters performed in predicting car-
diovascular (CV) events in a clinical cohort of patients
referred to PET-imaging for suspected CS.
METHODS
Study Population
We retrospectively screened all cardiac PET studies
performed in the Tampere University Hospital from August
2012 to September 2015. We excluded studies, in which the
clinical indication was not CS suspicion, if the patient’s
clinical data could not be obtained or PET-study was
performed for follow-up of previously diagnosed CS. Imaging
studies were also excluded if the dedicated imaging protocol
described below was not followed precisely. Altogether, 137
PET examinations were analyzed for the present study. In our
hospital, PET is routinely performed in the diagnostic workup
of possible CS. The reason for a clinical suspicion of CS was
one or more of the following: unexplained atrio-ventricular
(AV) block (n = 61), ventricular (n = 39), or supraventricular
(n = 13) arrhythmia, unexplained dilated cardiomyopathy
(n = 27), or unexplained low ejection fraction on echocardio-
graphy (n = 46), other echocardiographic ﬁndings suggestive
of CS (n = 53), or syncope (n = 27). The referring cardiologist
considered the symptoms and clinical ﬁndings as inconclusive
after routine evaluation, including clinical examination, ECG,
and echocardiography. Coronary angiography was performed
in cases with a clinical suspicion of coronary artery disease.
PET-Imaging
All patients underwent an integrated PET/CT (Discovery
STE 16, GE Healthcare, Milwaukee, WI, USA) examination.
To minimize physiological myocardial FDG-uptake, the
patients were instructed not to consume any carbohydrates
during the day before the imaging exam and to fast for 12 h
before the FDG injection. The patients maintained a food diary
during the prescribed diet. The patients were also instructed to
avoid heavy physical exercise to minimize FDG-uptake in
skeletal muscle. Patient height and weight were measured
before the administration of the radiopharmaceutical, and
blood glucose levels were tested to conﬁrm a level of\ 7
mmol/l. The PET/CT images were acquired approximately
60 min after the intravenous injection of FDG using the
Medrad Intego PET infusion system (Bayer Medical Care
Inc., Indianola, PA, USA). In our hospital, the activity injected
is based on the patient’s weight (3-3.2 MBq/kg). The imaging
protocol has been described in more detail previously.16
Analysis of PET Images
We classiﬁed the uptake pattern in the left ventricular
(LV) myocardium according to the recommendations of the
Japanese Society of Nuclear Cardiology as ‘none’ (no activity
exceeding normal blood pool activity), ‘global diffuse’ (uni-
form activity over the entire myocardium), ‘focal’ (focally
increased spot(s) of activity, other regions inactive), ‘focal on
diffuse’ (intense focal spot(s) of activity overlapping global
myocardial activity), or ‘diffuse non-global’ (faint activity on
at least two LV walls, but at least some areas of myocardium
with no activity over normal blood pool activity). Diffuse non-
global uptake is not mentioned in the Japanese Society of
Nuclear Cardiology recommendations but was considered to
be a similar physiological phenomenon as diffuse uptake. The
uptake was considered physiological if it was classiﬁed as
none, global diffuse, or diffuse non-global. Uptake was
considered pathological if it was classiﬁed as focal or focal
on diffuse. We also classiﬁed the uptake in the right ventricle
(RV) in a similar manner. The maximum standardized uptake
value (SUVmax) in the heart was measured and its location
was determined. Extracardiac uptake in the lymph nodes was
considered pathological if it exceeded that of the mediastinal
blood pool. The areas inspected for possible pathological
extracardiac uptake included lymph nodes in axillary,
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subclavicular, mediastinal, hilar, and epigastric sites. Patho-
logical FDG-uptake in the lung parenchyma, liver, spleen, and
bone marrow were also noted. Uptake in the liver, spleen and
lung parenchyma was considered pathological if there were
spots of metabolic activity exceeding the physiological uptake
of the surrounding parenchyma. Bone marrow uptake was
considered pathological if focal uptake exceeding that of the
liver was noted. The images were interpreted after patient
anonymization and randomization. The images were separately
interpreted by two experienced nuclear medicine physicians
(HT, 10 years of experience and KS, 15 years of experience)
blinded to all clinical data. In cases where the interpretation of
LV-uptake differed between the observers, a consensus was
reached and used in further analyses. After this initial analysis,
the quantitative parameters were measured using PETVCAR
software on GE Advantage workstation (GE Healthcare,
Milwaukee, WI, USA). Blood pool SUVmean was ﬁrst
measured from ascending aorta. A threshold for abnormal
cardiac uptake was deﬁned as blood pool SUVmean 9 1.5.
This value was used to delineate metabolic volume. SUVmean
over metabolic volume was measured and used to calculate
tCMA by multiplying the metabolic volume by SUVmean.14
Cut-off for high tCMA was deﬁned as 900 MBq that is
approximately tCMA ? 2SD in the group with no events.
Collection of Clinical Data
Clinical data were retrospectively collected from the
electronic medical record system of Tampere University
Hospital, which contains information from 2008 onward. We
collected demographic information, echocardiography ﬁnd-
ings, MRI-ﬁndings, relevant diagnoses, symptoms and
endomyocardial biopsy (EMB) ﬁndings, deaths, healthcare
visits, and hospitalizations for ventricular tachyarrhythmia.
Systolic function evaluated by echocardiography was catego-
rized as normal ([ 50%), decreased (35-50%) or
(poor\ 35%). Echocardiography ﬁndings were collected from
studies performed nearest to PET-study and the last echocar-
diography study of the follow-up period. Diagnosis of CS by
cardiologists was based on EMB or a combination of other
biopsy veriﬁcation of sarcoidosis and clinical and/or imaging
ﬁndings indicating cardiac involvement. Electronic health
record data for follow-up were available from the Tampere
University Hospital.
Cardiovascular Events
Cardiac events of interest were reduction in LVEF,
hospitalization due to cardiac arrhythmia, and death. Change in
LVEF was determined by comparing the ﬁndings between
echocardiography studies performed nearest to the PET-study
and the last study of the follow-up period. Decrease in LVEF
was deﬁned as a negative change in LVEF category deﬁned
above. We used hospital admission as a deﬁnition of severe
ventricular arrhythmia as the number of other detected
ventricular arrhythmias was highly dependent on whether or
not the patient had a pacemaker or implanted cardioverter-
deﬁbrillator (ICD).
Statistical Methods
Statistical analyses were performed using IBM SPSS
statistics version 22.0 (Armonk, NY, USA) and R software
version 3.2.2. T test was used to compare quantitative
metabolic parameters between patients, who had CV events
and those with no events. Comparison of quantitative param-
eters also included patients with physiological FDG-uptake.
Chi square test was used to test the statistical difference in
dichotomous variables between groups. Survival analysis was
performed with log-rank test.
RESULTS
Baseline characteristics, PET-ﬁndings and treat-
ment during follow-up for patients with and without CV
events are presented in Table 1. 35 (26%) patients had a
diagnosed sarcoidosis prior to imaging or during follow-
up. Cardiac sarcoidosis was diagnosed in 18 (13%)
patients and in 7 patients (5%) it was conﬁrmed by
EMB.
33 (24%) patients had pathological myocardial
FDG-uptake: 28 patients had a focal and 5 had a focal
on diffuse pattern. 12 patients (9%) had pathological
FDG-uptake in RV. All the patients with RV-uptake also
had LV-uptake. Of the 104 (76%) patients without
pathological uptake 85 (82%) had no visible uptake,
three (3%) had diffuse uptake over LV and 16 (15%) had
diffuse non-global uptake pattern. One patient had
diffuse and one had diffuse non-global uptake in RV
myocardium.
The follow-up time varied between 25.2 to
62.6 months (2.1-5.2 year), mean 54.7 months (3.74
years). Altogether, 11 patients had at least one event
during follow-up: seven were hospitalized because of
ventricular tachycardia, ﬁve had worsening of systolic
LV function and three patients died. There was no
signiﬁcant difference in baseline characteristics between
patients, who had events, and those who did not. Also,
cardiac events were not signiﬁcantly more common in
patients who were diagnosed with CS according to
diagnostic criteria.
CMR had been performed in 37 patients, of whom
19 (51%) had LGE. Of those 19 patients four (21%) had
a CV event during follow-up. In the subset of patients
with CMR data, all those subjects who had a CV event
also had LGE.
Cardiac SUVmax and tCMA were higher in patients
who had CV events compared to those with no events:
7.1 vs 4.4 and 530 MBq vs 163 MBq, respectively
(P\ .001 for both). There were 33 patients with
abnormal LV-uptake on PET and 12 of them had
abnormal uptake also in the RV. Five (15%) out of 33
patients with pathological cardiac uptake on PET had a
CV event on follow-up. All ﬁve had pathological uptake
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also in the RV. Pathological RV-uptake was signiﬁ-
cantly more common in patients with CV events
compared to those without events (P = .001). Event-
free survival curves in patients with and without
pathological RV-uptake are shown in Figure 1.
Eight patients had tCMA[ 900 MBq
and three (38%) of them had a CV event compared
to only 6% of those with tCMA\ 900 MBq. All these
three patients also had pathological RV-uptake. Patients
with pathological RV-uptake had signiﬁcantly higher
tCMA compared to those without RV-uptake: 914
(SD.706) vs. 123 (SD 356) MBq (P\ .001). There
were only 5 patients who had both high tCMA and RV-
uptake, and 3 (60%) of them had a CV event. Event-free
survival curves in patients with high and low tCMA are
shown in Figure 2.
In survival analysis, pathological RV-uptake was a
signiﬁcant predictor of cardiac events (P = .001). Also
high tCMA[ 900 MBq signiﬁcantly predicted events
(P = .032). Decreased baseline LVEF, pathological LV-
uptake or extracardiac FDG-uptake did not signiﬁcantly
Figure 1. Survival free of cardiac events in patients with no
right ventricular uptake and in those with pathological right
ventricular uptake. Between groups the P-value is .001.
Table 1. Baseline characteristics, PET-ﬁndings and treatment during follow-up in patients with and
without events during follow-up
Patients with events
n = 11
Patients with no events
n = 126
P-
value
Baseline characteristics
Female sex 45% (5) 43% (54) .556
Age, years (SD) 37 (8) 45 (13) .062
Follow-up, mo (SD) 50 (8) 44 (11) .059
Reduced LVEF at baseline 73% (8) 54% (68) .190
PET
Pathological LV-uptake 46% (5) 22% (28) .091
Pathological RV-uptake 46% (5) 6% (7) \ .001
tCMA[900 MBq 27% (3) 4% (5) .018
Extracardiac uptake 36% (4) 20% (25) .180
SUVmax 7.1 (5.6) 4.4 (2.8) \ .001
Metabolic volume (cm3) 105 (167) 44 (96) .050
tCMA (MBq) 530 (886) 163 (388) \ .001
Treatment
ICD 100% (11) 18% (12) \ .001
Anti-inﬂammatory medication 46% (5) 18% (22) .041
CS-diagnosis by the end of
follow-up
27% (3) 20% (15) .148
Values are % (n) for dichotomous and mean (SD) for continuous variables
LVEF, left ventricular ejection fraction; LV, left ventricle; RV, right ventricle, SUV, standardized uptake value; metabolic volume,
volume of myocardium with SUV[1.5 9 aortic reference SUV; SUVmean, mean SUV over pathological metabolic volume; tCMA,
total cardiac metabolic activity calculated as SUVmean 9 metabolic volume; ICD, implantable cardioverter-deﬁbrillator; CS,
cardiac sarcoidosis
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predict CV events during follow-up (P = .094, .217 and
.489, respectively).
DISCUSSION
We examined the value of cardiac FDG-PET in
predicting CV events in patients with a suspicion of CS.
Pathological RV-uptake was the strongest imaging-
related predictor of future CV events deﬁned as a
decrease in LVEF, hospitalization for ventricular tachy-
cardia (VT), or death. Also, the quantitative parameter
tCMA was a signiﬁcant predictor of events.
Decreased LVEF has been recognized as an impor-
tant predictor of long-term outcome in CS patients
treated with corticosteroids.7 In our population, the
majority of the patients who suffered for cardiac events
had decreased LVEF at baseline. However, decreased
LVEF had poor predictive value, as the majority of the
patients in our population were referred for imaging
because of unexplained cardiac failure. In fact, patho-
logical cardiac FDG-uptake was more common among
patients with normal LVEF that in those with cardiac
failure.16 This reﬂects the problem of recognizing the
patients with cardiac ﬁndings with increased risk for
major cardiac events.
Previously Blankstein et al. have reported that
pathological cardiac PET-ﬁndings predict VT and mor-
tality better than a CS-diagnosis by JMWH criteria and
independently of LVEF.12 FDG-uptake in the RV
indicated a ﬁvefold risk of cardiac events compared to
those with normal PET and myocardial perfusion in
their study. In another study, myocardial perfusion-
metabolism mismatch (metabolism assessed by PET)
was related to cardiac events in patients assessed for
possible cardiac sarcoidosis.13 PET has also been shown
to predict major cardiac events in patients with unex-
plained atrio-ventricular block, a common manifestation
of sarcoidosis.17
Furthermore, quantitative evaluation of myocardial
metabolic activity in PET has been shown to predict
cardiac events in some studies. Muser et al. showed that
a temporal decrease in tCMA indicated a lower risk of
events.18 Ishiyama et al. reported that SUVmax over all
sarcoidosis-involved organs better predicted response to
oral corticosteroids than tCMA in patients with CS. 19
LGE in CMR has been shown to be a strong
predictor of cardiac events in patients with proven
systemic sarcoidosis even in patients with preserved
LVEF.20,21 Bravo et al. studied PET and CMR in
patients with clinical manifestations of CS and found
that LGE predicted cardiac events similarly in PET-
positive and PET-negative patients. They concluded that
the risk of sustained VT and death were associated with
myocardial scarring but not to active inﬂammation.15
However, they did not analyze PET-ﬁndings beyond
negative/positive. Indeed, PET positivity per se was not
predictive of cardiac events in our population either. The
predictive value in our study was particularly associated
with pathological RV-uptake. Interestingly, Murtagh
et al. showed that ventricular dysfunction in addition to
the large burden of cardiac LGE denoted a high risk of
cardiac events.21 In another recent study, it was shown
that RV LGE predicted cardiac events.22 Both MRI and
PET studies conﬁrm the prognostic importance of
abnormal RV imaging ﬁndings. Moreover, electrophys-
iological studies have shown that RV scarring is a
common ﬁnding in CS patients with VT.23 RV scarring
was often found to be conﬂuent in comparison to patchy
scarring in the left ventricle, providing large amount of
substrate for re-entry circuits.24
In our population CMR was performed only in a
subset of 39 patients of whom 19 (51%) had LGE. There
was an association between reported LGE and CV
events (P-value .039). Signiﬁcantly, in this subset of
available CMR data, there were no CV events in patients
without LGE. Thus, negative CMR seems to have very
good negative predictive value. As the number of events
was low we could not perform further analyses for
independent role of PET-ﬁndings in this subgroup.
However, a signiﬁcant proportion of patients suspected
for CS had a pacemaker or ICD, and in those patients
CMR may not be feasible and for this reason we
consider our results on the prognostic role of PET-
ﬁndings relevant.
Figure 2. Survival free of cardiac events in patients with
tCMA below or above 900 MBq. Between groups the P-value
is .032.
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We also found that the quantitative parameter
tCMA predicts cardiac events. This is in line with the
results reported by Ahmadian et al., that high tCMA
predicts ventricular tachyarrhythmias and death.14 How-
ever, they did not report the possible pathological uptake
in RV. Sixty-three percent of our 8 patients in high
tCMA group had RV-uptake, and all the high tCMA
patients who had events also had pathological RV-
uptake. The combination of RV-uptake and high tCMA
signiﬁed 60% risk for events and should always be
communicated clearly to the clinician. Right ventricular
uptake is easily recognized while interpreting PET
studies making it a useful sign of high risk in every day
practice.
In our population, only a minority (13%) of patients
had sarcoidosis conﬁrmed by biopsy. Other diseases like
viral or giant cell myocarditis can cause pathological
myocardial uptake. Interestingly, patients with diag-
nosed CS did not have more cardiac events than those
without CS-diagnosis (Table 1). We consider this ﬁnd-
ing to be clinically signiﬁcant as cardiologists should
consider patients with a high burden of cardiac glycol-
ysis and/or right ventricular RV-uptake to be a high-risk
group whether or not they fulﬁll the diagnostic criteria
for CS.
We had access only to the information in the patient
record of Tampere University Hospital. Possible con-
tacts to other health care facilities were not recorded and
some endpoint events may have been missed. The
number of recorded cardiac events during follow-up was
relatively low. Due to the small number of events,
multivariable analysis was not feasible. Also, CMR data
were available only in a small proportion of the patients.
This prevented us from analyzing the effect of myocar-
dial scarring on the predictive value of PET-ﬁndings.
This, however, is often the clinical reality in patients
with a suspicion of CS due to conduction disturbances or
VT requiring a pacemaker or ICD. Our population is
heterogeneous and majority of the patients do not fulﬁll
diagnostic criteria for CS. However, the population is
representative of the true clinical situation and the
results can be applied to everyday clinical decision
making. Regrettably, we have no data on follow-up PET
studies. Changes in tCMA and RV-uptake status by
treatment and impact of these changes on prognosis will
be an interesting topic for future research. Our popula-
tion consists of white Caucasians and, as sarcoidosis is
known to have different representations in different
populations our results may not be generalizable to other
populations.
CONCLUSION
Among patients referred for FDG-PET imaging to
assess possible cardiac sarcoidosis, pathological right
ventricular uptake and a high burden of cardiac glycol-
ysis predict adverse cardiac events during follow-up. A
combination of pathological RV-uptake and high tCMA
signiﬁed very high risk for future CV events. Nuclear
medicine physicians should be aware of this and
communicate such ﬁndings clearly to the clinician.
NEW KNOWLEDGE GAINED
Pathological FDG-uptake in right ventricle is easy
to observe and should be considered as a signiﬁcant risk
marker in patients with suspected cardiac sarcoidosis
especially if present in combination with high total
cardiac metabolic activity.
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